

Comparison of Dynamic Treatment Regimes with An Ordinal Outcome

BY PALASH GHOSH

Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore
palash.ghosh@duke-nus.edu.sg,

AND BIBHAS CHAKRABORTY

Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore
Department of Statistics and Applied Probability, National University of Singapore, Singapore
Department of Biostatistics and Bioinformatics, Duke university, U.S.A.
bibhas.chakraborty@duke-nus.edu.sg

SUMMARY

Sequential multiple assignment randomized trials (SMART) are used to develop optimal treatment strategies for patients based on their medical histories in different branches of medical and behavioral sciences where a sequence of treatments are given to the patients; such sequential treatment strategies are often called dynamic treatment regimes. In the existing literature, the majority of the analysis methodologies for SMART studies assume a continuous primary outcome. However, ordinal outcomes are also quite common in medical practice; for example, the quality of life (poor, moderate, good) is an ordinal variable. In this work, first, we develop the notion of dynamic generalized odds-ratio ($dGOR$) to compare two dynamic treatment regimes embedded in a 2-stage SMART with an ordinal outcome. We propose a likelihood-based approach to estimate $dGOR$ from SMART data. Next, we discuss some results related to $dGOR$ and derive the asymptotic properties of its estimate. We derive the required sample size formula. Then, we extend the proposed methodology to a K -stage SMART. Finally, we discuss some alternative ways to estimate $dGOR$ using concordant-discordant pairs and multi-sample U -statistic. A simulation study shows the performance of the estimated $dGOR$ in terms of the estimated power corresponding to the derived sample size. We analyze data from STAR*D, a multistage randomized clinical trial for treating major depression, to illustrate the proposed methodology. A freely available online tool using R statistical software is provided to make the proposed method accessible to other researchers and practitioners.

Some key words: Generalized odds-ratio, distinct-path, shared-path, embedded regimes, STAR*D, sample size, response-rate.

1. INTRODUCTION

Personalized medicine is an increasingly important theme in biomedical research. Dynamic treatment regimes (DTRs) (Murphy, 2003; Robins, 2004) offer a vehicle to operationalize personalized medicine in time-varying treatment settings; they are often used in the management of chronic conditions where a patient is typically treated at multiple stages, e.g., alcohol and drug abuse (Lei et al., 2012), tobacco addiction (Chakraborty et al., 2010), chronic types of cancer (Thall et al., 2007; Zhao et al., 2011; Wang et al., 2012), HIV infection (Robins et al., 2008), and mental illnesses (Dawson & Lavori, 2004; Shortreed & Moodie, 2012; Chakraborty et al., 2013; Laber & Zhao, 2015; Song et al., 2015). Precisely, DTRs are decision rules that recommend sequences of treatments based on an individual patient's evolving treatment and covariate history. Once constructed based on data, these rules can be employed to give treatments to the patients to optimize the outcome, depending on the individual patient's medical history.

Sequential Multiple Assignment Randomized Trial (SMART) (Lavori & Dawson, 2000, 2004; Thall et al., 2000; Murphy, 2005) is a special kind of clinical trial that provides high-quality data for comparing or constructing DTRs; the data from such trials are less vulnerable to causal confounding than longitudinal observational data. Methodological research on SMARTs has been on the rise in recent years, in accordance with the increasing prevalence of SMART or similar designs in practice, e.g., in cancer (Wahed & Tsiatis, 2004; Auyeung et al., 2009; Mateos et al., 2010; Wang et al., 2012), depression (Rush et al., 2004; Kilbourne et al., 2014), schizophrenia (Schneider et al., 2001), childhood autism (Kasari, 2009), childhood attention deficit hyperactivity disorder (Nahum-Shani et al., 2012a,b), drug abuse during pregnancy (Jones, 2010), weight loss (Almirall et al., 2014) and alcoholism (Oslin, 2005). SMART designs involve randomization of patients to available treatment options at an initial stage, followed by re-randomizations at each subsequent stage of some or all of the patients to treatment options available at that stage. The re-randomizations and the set of treatment options at each stage may depend on information collected in prior stages such as how well the patient responded to the previous treatment. These designs attempt to conform better to the clinical practice, but still retain the well-known advantages of randomization over observational studies. A schematic diagram of a SMART design is presented in Figure 1, where for simplicity of illustration, we have considered only two stages of treatment; however, SMARTs can have more than two stages in general.

Various outcome types have been considered in the SMART design literature. For example, both Lavori & Dawson (2004) and Murphy (2005) considered primary analysis of SMART design with continuous outcomes; details about related sample size calculations under a variety of research questions were given by Oetting et al. (2011). These sample size calculations were further extended to cover binary outcomes by Ghosh et al. (2015). Binary outcomes from a SMART were analyzed previously via likelihood-based methods by Thall et al. (2000). A lot of attention in the literature was focussed on analysis of survival outcomes in a SMART (Wahed & Tsiatis, 2004, 2006; Feng & Wahed, 2008; Zhao et al., 2011; Kidwell & Wahed, 2013) and associated sample size calculations (Feng & Wahed, 2009; Li & Murphy, 2011). Composite outcomes were considered by Lizotte et al. (2012) and Wang et al. (2012). However, to the best of our knowledge, no one has developed any method for analyzing ordinal outcomes in a SMART design context till date, even though the outcomes of interest in many clinical and behavioral settings are measured in an ordinal scale and the methodologies to analyze such data in non-SMART




Fig. 1: A scheme of a hypothetical SMART design with two stages. The ‘R’ within a circle represents randomization.

context are available for decades (e.g., Agresti, 1980). The need for analysis methods to deal with ordinal outcomes in a SMART design has recently been acknowledged by Liu et al. (2014). The current article aims to address this critical knowledge gap in the literature.

Primary analysis of a SMART often involves comparison of embedded DTRs, the regimes that are naturally implemented within the trial by design. For example, in the SMART presented in Figure 1, there are four *embedded* DTRs, denoted as $d^{(1)} = (A, A^{R_A} E^{1-R_A})$, $d^{(2)} = (A, A^{R_A} F^{1-R_A})$, $d^{(3)} = (B, B^{R_B} E^{1-R_B})$, and $d^{(4)} = (B, B^{R_B} F^{1-R_B})$, where R_A and R_B are the indicators of response (1/0) corresponding to the initial treatments A and B , respectively. A patient whose treatment sequence is consistent with the regime $d^{(1)}$ is given the treatment A at the first stage, will continue with the same treatment if s/he is a responder ($R_A = 1$) to it, else will switch to the treatment E at the second stage if s/he is a nonresponder ($R_A = 0$); other embedded regimes can be interpreted in a similar fashion. When comparing embedded regimes in a SMART design of the type presented in Figure 1, one has to consider two types of comparison. First, note that among the above four regimes, both $d^{(1)}$ and $d^{(2)}$ start with the same initial treatment A , and thus the responders at the first stage to A are “shared” between both these regimes; in other words, the outcome data of the first-stage responders to A will contribute towards the performance metrics (e.g., mean outcome for continuous data) of both these regimes. Following Kidwell & Wahed (2013), we call $d^{(1)}$ and $d^{(2)}$ *shared-path* DTRs. Similarly, $d^{(3)}$ and $d^{(4)}$ constitute another pair of shared-path DTRs. In contrast, note that $d^{(1)}$ and $d^{(3)}$ (likewise, $d^{(2)}$ and $d^{(4)}$) start with different initial treatments, and thus performance metrics of $d^{(1)}$ and $d^{(3)}$ (likewise, $d^{(2)}$ and $d^{(4)}$) do not share any common group of trial subjects; they are referred to as *distinct-path* DTRs.

In this article, we will use the well-known *Sequenced Treatment Alternatives to Relieve Depression* (STAR*D) trial (Fava et al., 2003; Rush et al., 2004) for treating depression both to motivate and to empirically illustrate our methodological developments; see Section 10 for details about the STAR*D study. Suppose we want to compare any two embedded regimes in STAR*D, based on their *quality of life (QOL)* outcome after the use of various treatment sequences. In STAR*D, the *QOL* is an ordinal outcome, taking the ordered categorical values as 1 (very poor), 2 (poor), 3 (fair), 4 (good), and 5 (very good). The existing methods are not tailored to compare any two embedded regimes with respect to the ordinal variable *QOL*. However, the methodologies developed in this article will help to investigate such research questions properly; see Section 10 for further details.

A simple yet powerful approach to compare ordinal outcomes across two or more groups utilizes a key quantity called the *generalized odds ratio (GOR)*, first introduced by Agresti (1980) and later employed in the context of standard two-group randomized controlled trials (see, e.g., Lui & Chang, 2013). As the name suggests, the *GOR* is a generalization of the usual odds ratio, a quantity that is extensively used for binary data, e.g., in case of contingency tables and logistic regression. Our key contribution in the current article is to generalize the notion of *GOR* to more than one stages of the grouping variable (e.g., treatment) that can be applicable to a SMART design context; we call the resulting metric the *dynamic generalized odds ratio (dGOR)*.

The main difference between Agresti's *GOR* and our newly proposed *dGOR* is the presence of the response rate to the initial treatment within the definition of the odds ratio type quantity (note that these response rates can be different for different embedded regimes, as discussed in Section 3). Furthermore, as discussed in section 2.1, while the primary purpose of defining *dGOR* in the current article is to handle ordinal outcomes in a SMART, the definition of *dGOR* does not require the outcome to be ordinal as such; in fact in section 5.2, we show how to compute *dGOR* for continuous outcomes using *U*-statistics. Thus the scope of *dGOR* is very broad, and it opens up an alternative approach to compare DTRs beyond the standard methods based on mean outcomes or value functions (eg. Zhao et al., 2012, 2015a,b). We derive the asymptotic distribution of the *dGOR*, using which one can formally test the hypothesis of equality between two or more embedded DTRs in terms of their *dGORs*. Interestingly, the comparison between distinct-path regimes and that between shared-path regimes call for different considerations; hence we deal with these two cases separately. Next, we provide sample size calculation formula based on *dGORs*, and validate them via a thorough simulation study. We also extend the proposed methodology to a *K*-stage SMART. Furthermore, we develop a basic policy search algorithm that uses *dGOR* to find an optimal DTR within a finite class. Finally, we present the analysis of STAR*D data as an illustration of our proposed methodology. To facilitate wide dissemination, we have also developed a web application implementing the methodology, which is freely available online (<https://sites.google.com/site/palashghoshstat/sample-size-calculator>).

The rest of the article is organized as follows: we give a general framework in Section 2; in Sections 3 and 4, we discuss the comparison of two regimes having different initial treatments and same initial treatments, respectively; two alternative ways to estimate *dGOR* is discussed in Section 5; sample size formula is given in Section 6; we extend the proposed methodology to a *K*-stage SMART in Section 7; an algorithm for finding an optimal DTR within a finite class

using $dGOR$ is presented in Section 8; extensive simulation studies are shown in Section 9 and STAR*D data is analyzed in Section 10; Section 11 concludes the article with a discussion.

2. A GENERAL FRAMEWORK FOR COMPARING DTRS WITH ORDINAL OUTCOMES

2.1. Dynamic Generalized Odds Ratio

Let Y_1 and Y_2 be two ordinal random variables, denoting the primary outcomes corresponding to two groups (e.g., two treatment arms of a clinical trial): group 1 and 2 respectively, each taking values in J distinct ordered categories, say, $1, \dots, J$. Then the generalized odds-ratio (GOR) between group 2 and group 1 (Agresti, 1980; Lui & Chang, 2013) is defined as $GOR_{(2,1)} = \frac{P(Y_2 > Y_1)}{P(Y_2 < Y_1)}$. The interpretation of GOR is simple. Assuming that a higher category of the outcome variable is better, $GOR > 1$ indicates that the group 2 has a better outcome than group 1, and $GOR < 1$ indicates the other way round; finally $GOR = 1$ implies that there is no difference in outcomes between the two groups. In the following, we extend the above notion to define what we call a *dynamic generalized odds ratio* ($dGOR$), a metric that allows us to compare DTRs embedded in a SMART with ordinal outcomes.

To formally define the $dGOR$, we utilize the well-known *potential outcomes* framework (Rubin, 1974; Robins, 1997). Let T_1 and T_2 generically denote the treatments given to the patients at the first and second stages of the SMART considered in Figure 1 respectively, with $T_1 \in \{A, B\}$, $T_2 \in \{A, E, F\}$ if $T_1 = A$, and $T_2 \in \{B, E, F\}$ if $T_1 = B$. Let $Y_{T_1 T_2}$ be the potential outcome under the treatment sequence (T_1, T_2) . Note that with respect to the SMART design under consideration, there are only six potential outcomes, viz., $Y_{AA}, Y_{AE}, Y_{AF}, Y_{BB}, Y_{BE}$ and Y_{BF} . Then the potential outcome under any DTR in the current setup can be written in terms of the above six potential outcomes, as shown below.

Consider the longitudinal data trajectory (O_1, T_1, O_2, T_2, Y) corresponding to an individual patient participating in the SMART, where O_k denotes the pre-treatment observations at stage k ($k = 1, 2$), T_k is the treatment given at stage k ($k = 1, 2$) as defined before, and Y is the primary outcome. Note that the response indicator R_{T_1} can be subsumed in O_2 (R_{T_1} can be either a component or a low-dimensional summary of the vector-valued O_2). Furthermore, define the history variables as $H_1 = O_1$ and $H_2 = (O_1, T_1, O_2)$. Any arbitrary DTR g with respect to the above data structure can be defined as a vector of decision rules, $g = (g_1, g_2)$, where $g_1(H_1) \in \mathcal{A}_1$ and $g_2(H_2) \in \mathcal{A}_2$, with \mathcal{A}_k denoting the class of treatment options at stage k ($k = 1, 2$). Then the potential outcome under the arbitrary DTR g can be defined as

$$\begin{aligned} Y_g = & Y_{AA}I\{g_1(H_1) = A, g_2(H_2) = A\} \\ & + Y_{AE}I\{g_1(H_1) = A, g_2(H_2) = E\} \\ & + Y_{AF}I\{g_1(H_1) = A, g_2(H_2) = F\} \\ & + Y_{BB}I\{g_1(H_1) = B, g_2(H_2) = B\} \\ & + Y_{BE}I\{g_1(H_1) = B, g_2(H_2) = E\} \\ & + Y_{BF}I\{g_1(H_1) = B, g_2(H_2) = F\}, \end{aligned}$$

where $I\{\cdot\}$ is an indicator function. Now we are in a position to define $dGOR$ as follows.

DEFINITION 1. Let Y_g and $Y_{g'}$ denote the potential outcomes under two dynamic regimes g and g' . Then the dynamic generalized odds ratio ($dGOR$) between g and g' , denoted $\eta_{g,g'}$, is defined as

$$\eta_{g,g'} = \frac{P(Y_g > Y_{g'})}{P(Y_g < Y_{g'})}. \quad (1)$$

where $P(Y_g > Y_{g'})$ is the probability that the outcome for a randomly selected patient from the set of patients whose treatment sequence is consistent with the regime g is larger than the outcome for a randomly selected patient from the set of patients whose treatment sequence is consistent with the regime g' .

Next, we assume that the usual assumptions about potential outcomes (Robins, 1997, 2004) in a longitudinal setting, viz., (i) *consistency* and (ii) *no unmeasured confounding*, hold. Specifically, the consistency assumption states that the potential outcome under the observed treatment sequence and the observed outcome agree, i.e., $Y = Y_{T_1 T_2}$ if the observed treatment sequence is indeed (T_1, T_2) . Thus, while the $dGOR$ is defined conceptually using potential outcomes, it can be computed based on observed data. On the other hand, the no unmeasured confounding assumption states that treatment allocation is independent of future potential outcomes given the history; this is satisfied by design in case of SMARTs (Murphy, 2005).

Remark 1. Even though our main focus in this article is to define and use $dGOR$ for comparing DTRs with ordinal outcomes, the above definition does not require Y_g and $Y_{g'}$ to be ordinal variables. In fact, as discussed by Agresti (1980) in the context of GOR , the $dGOR$ can as well be used to compare DTRs based on continuous outcomes. Furthermore, the above definition does not assume any particular parametric model for the data. Thus the scope of $dGOR$ is very broad, and it provides an alternative approach to comparing DTRs beyond the standard methods based on mean potential outcomes or *value functions* (Zhao et al., 2012, 2015a,b); the value function of a regime g is defined as $E(Y_g)$. Thus, while value-based methods work with mean potential outcomes, $dGOR$ -based methods work with stochastic ordering of potential outcomes.

Remark 2. In this article, we develop $dGOR$ mainly for a 2-stage SMART. However, in Section 7, we derive the $dGOR$ corresponding to any two embedded regimes in a SMART with more than two stages. In Section 8, we also show how to use $dGOR$ to find an optimal regime withing a finite class. For a single stage SMART (i.e., an RCT), $dGOR$ becomes GOR .

3. COMPARISON OF TWO DISTINCT-PATH EMBEDDED DYNAMIC REGIMES

3.1. Definition, estimation and asymptotic distribution of $dGOR$ for comparing distinct-path regimes

Without loss of generality, suppose we are interested in comparing two distinct-path embedded dynamic regimes $d^{(1)} = (A, A^{R_A} E^{1-R_A})$ and $d^{(3)} = (B, B^{R_B} E^{1-R_B})$, as previously defined in Section 1. Here, R_A and R_B denote the response indicators (1 for responder, 0 for non-responder); note that $R_A = I\{d_1^{(1)}(H_1) = d_2^{(1)}(H_2) = A\}$ and $R_B = I\{d_1^{(3)}(H_1) = d_2^{(3)}(H_2) = B\}$. Also, let $Y_{d^{(1)}}$ denotes the primary outcome of a randomly selected patient from the set of patients whose treatment sequence is consistent with the regime $d^{(1)}$. Similarly, $Y_{d^{(3)}}$

denotes the same corresponds to the regime $d^{(3)}$. Then,

$$\begin{aligned}
& P(Y_{d^{(3)}} > Y_{d^{(1)}}) \\
&= P(R_A R_B = 1) \times P(Y_{d^{(3)}} > Y_{d^{(1)}} | R_A R_B = 1) \\
&\quad + P(R_A(1 - R_B) = 1) \times P(Y_{d^{(3)}} > Y_{d^{(1)}} | R_A(1 - R_B) = 1) \\
&\quad + P((1 - R_A)R_B = 1) \times P(Y_{d^{(3)}} > Y_{d^{(1)}} | (1 - R_A)R_B = 1) \\
&\quad + P((1 - R_A)(1 - R_B) = 1) \times P(Y_{d^{(3)}} > Y_{d^{(1)}} | (1 - R_A)(1 - R_B) = 1) \\
&= \sum_{R_A, R_B \in \{0,1\}} \sum_{u=1}^{J-1} \sum_{s=u+1}^J \left\{ \gamma_A^{R_A} \gamma_B^{R_B} (1 - \gamma_A)^{1-R_A} (1 - \gamma_B)^{1-R_B} \right. \\
&\qquad \qquad \qquad \left. \times \pi_{AA^{R_A} E^{1-R_A, u}} \pi_{BB^{R_B} E^{1-R_B, s}} \right\},
\end{aligned}$$

where u corresponds to the regime $d^{(1)}$ and s corresponds to the regime $d^{(3)}$. $\pi_{AA, u} = \pi_u(T_1 = A, T_2 = A)$, $\pi_{AE, u} = \pi_u(T_1 = A, T_2 = E)$, $\pi_{BB, s} = \pi_s(T_1 = B, T_2 = B)$ and $\pi_{BE, s} = \pi_s(T_1 = B, T_2 = E)$. Similarly $P(Y_{d^{(3)}} < Y_{d^{(1)}})$ can be computed. Hence, from (1) the $dGOR$ is given by

$$\eta_{d^{(3)}, d^{(1)}}^{\text{DP}} = \frac{\sum_{R_A, R_B \in \{0,1\}} \sum_{u=1}^{J-1} \sum_{s=u+1}^J \gamma_A^{R_A} \gamma_B^{R_B} (1 - \gamma_A)^{1-R_A} (1 - \gamma_B)^{1-R_B} \times \pi_{AA^{R_A} E^{1-R_A, u}} \pi_{BB^{R_B} E^{1-R_B, s}}}{\sum_{R_A, R_B \in \{0,1\}} \sum_{u=2}^J \sum_{s=1}^{u-1} \gamma_A^{R_A} \gamma_B^{R_B} (1 - \gamma_A)^{1-R_A} (1 - \gamma_B)^{1-R_B} \times \pi_{AA^{R_A} E^{1-R_A, u}} \pi_{BB^{R_B} E^{1-R_B, s}}}, \quad (2)$$

where the superscript ‘‘DP’’ indicates the two regimes under comparison are distinct-path regimes. The statement $\eta_{d^{(3)}, d^{(1)}} > 1$ indicates the regime $d^{(3)}$ has a better outcome than the regime $d^{(1)}$ (considering higher values corresponds to better outcomes). Note that, for $J = 2$, i.e. for binary outcome data, the above expression boils down to

$$\eta_{d^{(3)}, d^{(1)}}^{\text{DP}} = \frac{\sum_{R_A, R_B \in \{0,1\}} \gamma_A^{R_A} \gamma_B^{R_B} (1 - \gamma_A)^{1-R_A} (1 - \gamma_B)^{1-R_B} \times \pi_{AA^{R_A} E^{1-R_A, 1}} \pi_{BB^{R_B} E^{1-R_B, 2}}}{\sum_{R_A, R_B \in \{0,1\}} \gamma_A^{R_A} \gamma_B^{R_B} (1 - \gamma_A)^{1-R_A} (1 - \gamma_B)^{1-R_B} \times \pi_{AA^{R_A} E^{1-R_A, 2}} \pi_{BB^{R_B} E^{1-R_B, 1}}}, \quad (3)$$

which we can call a *dynamic odds ratio* (dOR). This dOR can reduce to the traditional odds ratio, $\pi_{AE, 1} \pi_{BE, 2} / \pi_{AE, 2} \pi_{BE, 1}$, only when there is no split of trial subjects according to their response/non-response statuses at the end of stage 1 (all non-responders); such a situation arises in a SMART involving smoking cessation interventions (Strecher et al., 2008; Chakraborty et al., 2010).

The maximum likelihood estimate of $\eta_{d^{(3)}, d^{(1)}}^{\text{DP}}$, say $\hat{\eta}_{d^{(3)}, d^{(1)}}^{\text{DP}}$, can be computed by plugging-in the maximum likelihood estimates of γ s (empirical response rates) and π s (empirical probabilities of outcome categories) obtained from the likelihood (see Appendix, Section 12.1). The asymptotic distribution of $dGOR$ in (2) is given by

$$\sqrt{N} \left(\log(\hat{\eta}_{d^{(3)}, d^{(1)}}^{\text{DP}}) - \log(\eta_{d^{(3)}, d^{(1)}}^{\text{DP}}) \right) \rightarrow \text{Normal}(0, \sigma_{d^{(3)}, d^{(1)}}^2), \quad (4)$$

where $N^{-1} \sigma_{d^{(3)}, d^{(1)}}^2$ is the variance of $\log(\hat{\eta}_{d^{(3)}, d^{(1)}}^{\text{DP}})$. See the Appendix for detailed derivation.

Note that, $\eta_{d^{(3)},d^{(1)}}^{\text{DP}}$ in (2) can be alternatively defined as

$$\eta_{d^{(3)},d^{(1)}}^{\text{DP}} = \frac{\sum_{R_A, R_B \in \{0,1\}} \left\{ \gamma_A^{R_A} \gamma_B^{R_B} (1 - \gamma_A)^{1-R_A} (1 - \gamma_B)^{1-R_B} \right.}{\sum_{R_A, R_B \in \{0,1\}} \left\{ \gamma_A^{R_A} \gamma_B^{R_B} (1 - \gamma_A)^{1-R_A} (1 - \gamma_B)^{1-R_B} \right.} \times \frac{\left[\mathbf{1}'(\mathbf{U}(\Pi_{AA}^{R_A} \Pi_{BB}^{R_B} \mathbf{E}^{1-R_A} \mathbf{E}^{1-R_B}) - \text{diag}(\Pi_{AA}^{R_A} \Pi_{BB}^{R_B} \mathbf{E}^{1-R_A} \mathbf{E}^{1-R_B})) \mathbf{1} \right]}{\left[\mathbf{1}'(\mathbf{L}(\Pi_{AA}^{R_A} \Pi_{BB}^{R_B} \mathbf{E}^{1-R_A} \mathbf{E}^{1-R_B}) - \text{diag}(\Pi_{AA}^{R_A} \Pi_{BB}^{R_B} \mathbf{E}^{1-R_A} \mathbf{E}^{1-R_B})) \mathbf{1} \right]} \quad (5)$$

where the column vector $\Pi_{T_1 T_1^{R_{T_1}} T_2^{1-R_{T_1}}} = (\Pi_{T_1 T_1^{R_{T_1}} T_2^{1-R_{T_1}}, 1}, \dots, \Pi_{T_1 T_1^{R_{T_1}} T_2^{1-R_{T_1}}, J})'$; $d \in \{d^{(1)}, d^{(3)}\}$. Then $\mathbf{U}(\mathbf{Z})$, $\mathbf{L}(\mathbf{Z})$ and $\text{diag}(\mathbf{Z})$ denote upper-triangular-part, lower-triangular-part and diagonal-part of a square matrix \mathbf{Z} after replacing other elements by zeros, respectively. For example,

$$Z = \begin{bmatrix} a & b & c \\ d & e & f \\ g & h & i \end{bmatrix} \text{ implies } \mathbf{U}(\mathbf{Z}) = \begin{bmatrix} a & b & c \\ 0 & e & f \\ 0 & 0 & i \end{bmatrix}, \mathbf{L}(\mathbf{Z}) = \begin{bmatrix} a & 0 & 0 \\ d & e & 0 \\ g & h & i \end{bmatrix} \text{ and } \text{diag}(\mathbf{Z}) = \begin{bmatrix} a & 0 & 0 \\ 0 & e & 0 \\ 0 & 0 & i \end{bmatrix}.$$

The expression of $\eta_{d^{(3)},d^{(1)}}^{\text{DP}}$ in (5) is computationally relatively easy to work with. If we assume the cell probabilities of the ordinal outcome in the two responder arms (and the two non-responder arms) are same in two embedded distinct-path regimes, then the following theorem states the relationship between the $dGOR$ and the two response probabilities corresponding to the two distinct-path regimes.

THEOREM 1. *Let $\Pi_{AA} = \Pi_{BB}$ and $\Pi_{AE} = \Pi_{BE}$,*

- i) *then $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} = 1$ iff $\gamma_A = \gamma_B$,*
- ii) *furthermore, let $\mathbf{1}'(\mathbf{U}(\Pi_{AA} \Pi_{BE}') \mathbf{1}) \geq \mathbf{1}'(\mathbf{L}(\Pi_{AA} \Pi_{BE}') \mathbf{1})$, then $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} \geq 1$ iff $\gamma_A \geq \gamma_B$.*

Proof: i) **If part:** Let $\Pi_{AA} = \Pi_{BB}$, $\Pi_{AE} = \Pi_{BE}$ and we assume $\gamma_A = \gamma_B$. Using the property for any square matrix Z , $\mathbf{1}'\mathbf{U}(Z)\mathbf{1} = \mathbf{1}'\mathbf{L}(Z)\mathbf{1}$, it is trivial to show that the numerator and the denominator of $\eta_{d^{(3)},d^{(1)}}^{\text{DP}}$ in (5) are exactly same. Hence, $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} = 1$.

Only if part: Let $\Pi_{AA} = \Pi_{BB}$, $\Pi_{AE} = \Pi_{BE}$ and $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} = 1$, we want to show that $\gamma_A = \gamma_B$. We have

$$\begin{aligned} \eta_{d^{(3)},d^{(1)}}^{\text{DP}} &= 1 \\ \implies \gamma_A(1 - \gamma_B) [\mathbf{1}'(\mathbf{U}(\Pi_{AA} \Pi_{BE}')) \mathbf{1}] + (1 - \gamma_A)\gamma_B [\mathbf{1}'(\mathbf{U}(\Pi_{AE} \Pi_{BB}')) \mathbf{1}] \\ &= \gamma_A(1 - \gamma_B) [\mathbf{1}'(\mathbf{L}(\Pi_{AA} \Pi_{BE}')) \mathbf{1}] + (1 - \gamma_A)\gamma_B [\mathbf{1}'(\mathbf{L}(\Pi_{AE} \Pi_{BB}')) \mathbf{1}] \\ \implies \gamma_A(1 - \gamma_B) [\mathbf{1}'(\mathbf{U}(\Pi_{AA} \Pi_{BE}')) \mathbf{1} - \mathbf{1}'(\mathbf{L}(\Pi_{AA} \Pi_{BE}')) \mathbf{1}] \\ &= (1 - \gamma_A)\gamma_B [\mathbf{1}'(\mathbf{L}(\Pi_{AE} \Pi_{BB}')) \mathbf{1} - \mathbf{1}'(\mathbf{U}(\Pi_{AE} \Pi_{BB}')) \mathbf{1}] \\ \implies \gamma_A(1 - \gamma_B) &= (1 - \gamma_A)\gamma_B \\ \implies \gamma_A &= \gamma_B. \end{aligned}$$

ii) **if part:** Here we assume $\gamma_A \geq \gamma_B$ and show that $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} \geq 1$, respectively. Let $\gamma_A > \gamma_B$. We have

$$\begin{aligned} & [1'(\mathbf{U}(\mathbf{\Pi}_{\text{AA}}\mathbf{\Pi}'_{\text{BE}}))\mathbf{1} - 1'(\mathbf{L}(\mathbf{\Pi}_{\text{AA}}\mathbf{\Pi}'_{\text{BE}}))\mathbf{1}] \\ & \quad = [1'(\mathbf{L}(\mathbf{\Pi}_{\text{AE}}\mathbf{\Pi}'_{\text{BB}}))\mathbf{1} - 1'(\mathbf{U}(\mathbf{\Pi}_{\text{AE}}\mathbf{\Pi}'_{\text{BB}}))\mathbf{1}] > 0 \\ \implies & \gamma_A(1 - \gamma_B)[1'(\mathbf{U}(\mathbf{\Pi}_{\text{AA}}\mathbf{\Pi}'_{\text{BE}}))\mathbf{1} - 1'(\mathbf{L}(\mathbf{\Pi}_{\text{AA}}\mathbf{\Pi}'_{\text{BE}}))\mathbf{1}] \\ & \quad > (1 - \gamma_A)\gamma_B[1'(\mathbf{L}(\mathbf{\Pi}_{\text{AE}}\mathbf{\Pi}'_{\text{BB}}))\mathbf{1} - 1'(\mathbf{U}(\mathbf{\Pi}_{\text{AE}}\mathbf{\Pi}'_{\text{BB}}))\mathbf{1}] \\ \implies & \eta_{d^{(3)},d^{(1)}}^{\text{DP}} > 1. \end{aligned}$$

Similarly, $\gamma_A < \gamma_B$ implies $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} < 1$.

Only if part: This can be proved by replacing “ = ” by “ > ” and “ < ” one at a time in the only-if-part of i).

In contrast with Theorem 1, if we assume the cell probabilities of the ordinal outcome in the responder arm of one regime are same as the cell probabilities of the non-responder arm of the other regime in two embedded distinct-path regimes, then the following theorem states the relationship between the $d\text{GOR}$ and the two response probabilities corresponding to the two distinct-path regimes.

THEOREM 2. Let $\mathbf{\Pi}_{\text{AA}} = \mathbf{\Pi}_{\text{BE}}$ and $\mathbf{\Pi}_{\text{AE}} = \mathbf{\Pi}_{\text{BB}}$,

- i) then $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} = 1$ iff $\gamma_A = 1 - \gamma_B$,
ii) furthermore, let $1'(\mathbf{U}(\mathbf{\Pi}_{\text{AA}}\mathbf{\Pi}'_{\text{BB}}))\mathbf{1} \geq 1'(\mathbf{L}(\mathbf{\Pi}_{\text{AA}}\mathbf{\Pi}'_{\text{BB}}))\mathbf{1}$, then $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} \geq 1$ iff $\gamma_A \geq 1 - \gamma_B$.

Proof: Following the similar arguments as in the proofs of *Theorem 1*, *Theorem 2* can be proved.

4. COMPARISON OF TWO SHARED-PATH EMBEDDED DYNAMIC REGIMES

4.1. Definition, estimation and asymptotic distribution of $d\text{GOR}$ for comparing shared-path regimes

In this section, we are interested in comparing two shared-path dynamic regimes, using the same notations described in Section (3.1) (Kidwell & Wahed, 2013). Without loss of generality, let us consider two shared-path regimes $d^{(1)} : (A, A^{R_A} E^{1-R_A})$ and $d^{(2)} : (A, A^{R'_A} F^{1-R'_A})$. Here, $R_A = I\{d_1^{(1)}(H_1) = A, d_2^{(1)}(H_2) = A\}$ and $R'_A = I\{d_1^{(2)}(H_1) = A, d_2^{(2)}(H_2) = A\}$ denote the response indicators (1 for responder, 0 for non-responder) for the two randomly selected patients from the regimes $d^{(1)}$ and $d^{(2)}$, respectively. Also, let $Y_{d^{(1)}}$ and $Y_{d^{(2)}}$ denote their primary outcomes. Now we have,

$$\begin{aligned} & P(Y_{d^{(2)}} > Y_{d^{(1)}}) \\ & = P(R_A R'_A = 1) \times P(Y_{d^{(2)}} > Y_{d^{(1)}} | R_A R'_A = 1) \\ & \quad + P(R_A(1 - R'_A) = 1) \times P(Y_{d^{(2)}} > Y_{d^{(1)}} | R_A(1 - R'_A) = 1) \\ & \quad + P((1 - R_A)R'_A = 1) \times P(Y_{d^{(2)}} > Y_{d^{(1)}} | (1 - R_A)R'_A = 1) \\ & \quad + P((1 - R_A)(1 - R'_A) = 1) \times P(Y_{d^{(2)}} > Y_{d^{(1)}} | (1 - R_A)(1 - R'_A) = 1). \end{aligned}$$

Clearly, $P(R_A R'_A = 1) = \gamma_A^2$, $P(R_A(1 - R'_A) = 1) = P((1 - R_A)R'_A = 1) = \gamma_A(1 - \gamma_A)$, and $P((1 - R_A)(1 - R'_A) = 1) = (1 - \gamma_A)^2$. Thus,

$$\begin{aligned} & P(Y_{d^{(2)}} > Y_{d^{(1)}}) \\ &= \sum_{R_A, R'_A \in \{0,1\}} \sum_{u=1}^{J-1} \sum_{s=u+1}^J \gamma_A^{R_A+R'_A} (1 - \gamma_A)^{2-R_A-R'_A} \times \pi_{AA^{R_A}E^{1-R_A},u} \pi_{AA^{R'_A}F^{1-R'_A},s} \end{aligned}$$

Similarly $P(Y_{d^{(2)}} < Y_{d^{(1)}})$ can be computed. Hence, from (1) the $dGOR$ is given by

$$\eta_{d^{(2)},d^{(1)}}^{\text{SP}} = \frac{\sum_{R_A, R'_A \in \{0,1\}} \sum_{u=1}^{J-1} \sum_{s=u+1}^J \gamma_A^{R_A+R'_A} (1 - \gamma_A)^{2-R_A-R'_A} \times \pi_{AA^{R_A}E^{1-R_A},u} \pi_{AA^{R'_A}F^{1-R'_A},s}}{\sum_{R_A, R'_A \in \{0,1\}} \sum_{u=2}^J \sum_{s=1}^{u-1} \gamma_A^{R_A+R'_A} (1 - \gamma_A)^{2-R_A-R'_A} \times \pi_{AA^{R_A}E^{1-R_A},u} \pi_{AA^{R'_A}F^{1-R'_A},s}}, \quad (6)$$

where the superscript ‘‘SP’’ indicates that the two regimes under comparison are shared-path regimes.

Remark 3. The $dGOR$, $\eta_{d^{(2)},d^{(1)}}^{\text{SP}}$ given in (6) to compare two shared-path regimes is a special case of $dGOR$, $\eta_{d^{(3)},d^{(1)}}^{\text{DP}}$ defined in (2); $\eta_{d^{(2)},d^{(1)}}^{\text{SP}}$ can be obtained from the $\eta_{d^{(3)},d^{(1)}}^{\text{DP}}$ by replacing $d^{(3)}$, γ_B and R_B by $d^{(2)}$, γ_A and R'_A , respectively.

Note that $\eta_{d^{(2)},d^{(1)}}^{\text{SP}}$ in (6) can be alternatively defined as

$$\begin{aligned} & \eta_{d^{(2)},d^{(1)}}^{\text{SP}} \\ &= \frac{\sum_{R_A, R'_A \in \{0,1\}} \gamma_A(R_A, R'_A) [\mathbf{1}'(\mathbf{U}(\mathbf{\Pi}_{AA^{R_A}E^{1-R_A}} \mathbf{\Pi}'_{AA^{R'_A}F^{1-R'_A}}) - \text{diag}(\mathbf{\Pi}_{AA^{R_A}E^{1-R_A}} \mathbf{\Pi}'_{AA^{R'_A}F^{1-R'_A}})) \mathbf{1}]}{\sum_{R_A, R'_A \in \{0,1\}} \gamma_A(R_A, R'_A) [\mathbf{1}'(\mathbf{L}(\mathbf{\Pi}_{AA^{R_A}E^{1-R_A}} \mathbf{\Pi}'_{AA^{R'_A}F^{1-R'_A}}) - \text{diag}(\mathbf{\Pi}_{AA^{R_A}E^{1-R_A}} \mathbf{\Pi}'_{AA^{R'_A}F^{1-R'_A}})) \mathbf{1}]} \end{aligned}$$

where $\gamma_A(R_A, R'_A) = \gamma_A^{R_A+R'_A} (1 - \gamma_A)^{2-R_A-R'_A}$.

The maximum likelihood estimate of $\eta_{d^{(2)},d^{(1)}}^{\text{SP}}$, say $\hat{\eta}_{d^{(2)},d^{(1)}}^{\text{SP}}$, can be computed by plugging-in the maximum likelihood estimates of γ s (empirical response rates) and π s (empirical probabilities of outcome categories), as before. The asymptotic distribution is given by

$$\sqrt{N} \left(\log(\hat{\eta}_{d^{(2)},d^{(1)}}^{\text{SP}}) - \log(\eta_{d^{(2)},d^{(1)}}^{\text{SP}}) \right) \rightarrow \text{Normal}(0, \sigma_{d^{(2)},d^{(1)}}^2), \quad (7)$$

where $N^{-1} \sigma_{d^{(2)},d^{(1)}}^2$ is the variance of $\log(\hat{\eta}_{d^{(2)},d^{(1)}}^{\text{SP}})$. See the Appendix for detailed derivation.

Remark 4. Note that, $\mathbf{\Pi}_{AE} = \mathbf{\Pi}_{AF}$ implies $\eta_{d^{(2)},d^{(1)}}^{\text{SP}} = 1$. However, the converse is not true. We illustrate this point with the following example. Let $\Pi_{AA} = (0.2, 0.3, 0.5)$, $\Pi_{AE} = (0.12, 0.32, 0.56)$, $\Pi_{AF} = (0.06, 0.41, 0.53)$ and $\gamma_A = 0.2$, here $dGOR = 1$ even though $\mathbf{\Pi}_{AE} \neq \mathbf{\Pi}_{AF}$. Also $\eta_{d^{(2)},d^{(1)}}^{\text{SP}}$ is not invariant in $\mathbf{\Pi}_{AA}$. Consider two values of $\mathbf{\Pi}_{AA}$ as $(0.5, 0.4, 0.1)$ and $(0.2, 0.4, 0.4)$. It can be shown that for $\gamma_A = 0.2$, $\eta_{d^{(2)},d^{(1)}}^{\text{SP}}$ values are different in two cases (0.43 and 0.45) when both $\mathbf{\Pi}_{AE}$ and $\mathbf{\Pi}_{AF}$ are fixed at $(0.3, 0.3, 0.4)$ and $(0.6, 0.2, 0.2)$, respectively.

5. ALTERNATIVE WAYS TO ESTIMATE $dGOR$ 5.1. $dGOR$ based on Concordant and Discordant pairs

Goodman & Kruskal (1954) proposed a measure of association Γ for a $I \times J$ cross-classified table; where I represents the number of ordinal categories of the row variable and J denotes the same for the column variable. The Goodman-Kruskal Γ is based on the number of concordant and discordant pairs corresponding to any two individuals randomly chosen from the population. Let the two chosen individuals be denoted by (i, j) and (i', j') , where $i, i' = 1, \dots, I$ and $j, j' = 1, \dots, J$. The chosen pair (two individuals) is called concordant if $(i < i'$ and $j < j')$ or $(i > i'$ and $j > j')$. On the other hand, the chosen pair is discordant if $(i < i'$ and $j > j')$ or $(i > i'$ and $j < j')$. Note that, the GOR described in the current article is not defined for a $I \times J$ cross-classified table; rather, we can think of a $2 \times J$ table where two rows denote two different sub-populations (e.g., two arms of a trial) and the columns correspond to the J ordered categories of an ordinal variable Y . However, we can calculate GOR based on the number of concordant and discordant pairs in a slightly different manner. Suppose a randomly selected individual from the first row (say, sub-population 1) is denoted by $(1, u)$ and similarly, a randomly selected individual from the second row (say, sub-population 2) is denoted by $(2, s)$; $u, s = 1, \dots, J$. Define the randomly selected pair (with respect to $GOR_{(2,1)}$) to be concordant if $u < s$, i.e., the individual selected from population 2 has higher response category than the individual selected from population 1. Under the same setup, define the pair to be discordant if $u > s$. Thus, the total number of concordant and discordant pairs are given by $\sum_{u=1}^{J-1} \sum_{s=u+1}^J n_{1u}n_{2s}$ and $\sum_{u=2}^J \sum_{s=1}^{u-1} n_{1u}n_{2s}$, respectively, where n_{ik} denotes the cell frequency corresponding to the i^{th} sub-population and the k^{th} ordinal category with $i = 1, 2; k = 1, \dots, J$. An estimate of the probability $P(Y_2 > Y_1)$ can be given as $\frac{1}{n_1 \cdot n_2} \cdot \sum_{u=1}^{J-1} \sum_{s=u+1}^J n_{1u}n_{2s}$, where $n_i = \sum_{u=1}^J n_{iu}$, $i = 1, 2$. We can write $GOR_{(2,1)}$ as the ratio of the total number of concordant pairs over the total number of discordant pairs as

$$\widehat{GOR}_{(2,1)} = \frac{\sum_{u=1}^{J-1} \sum_{s=u+1}^J n_{1u}n_{2s}}{\sum_{u=2}^J \sum_{s=1}^{u-1} n_{1u}n_{2s}}.$$

In a similar fashion, we can easily express the estimate of $dGOR$ defined in (2) as

$$\begin{aligned} & \hat{\eta}_{d^{(3)}, d^{(1)}}^{DP} \\ &= \frac{\sum_{u=1}^{J-1} \sum_{s=u+1}^J \left[n_{AA,u}n_{BB,s} + 2 \times n_{AA,u}n_{BE,s} + 2 \times n_{AE,u}n_{BB,s} + 4 \times n_{AE,u}n_{BE,s} \right]}{\sum_{u=2}^J \sum_{s=1}^{u-1} \left[n_{AA,u}n_{BB,s} + 2 \times n_{AA,u}n_{BE,s} + 2 \times n_{AE,u}n_{BB,s} + 4 \times n_{AE,u}n_{BE,s} \right]}, \quad (8) \end{aligned}$$

where $n_{AA,u}$ denotes the cell frequency of the u^{th} ordinal category in the responder arm of the regime $d^{(1)}$; other cell frequencies are defined accordingly. Note that, total number of individuals in the responder arm of the regime $d^{(1)}$ is $n_{AA} = \sum_{u=1}^J n_{AA,u} = \frac{N}{2} \times \hat{\gamma}_A$, where N is the known total number of individuals in the entire SMART. In (8), the four components in the numerator (or the denominator) refer to the four different ways of choosing a pair of individuals from the two regimes $d^{(1)}$ and $d^{(3)}$. Specifically, we have the set as $\{(AA, BB), (AA, BE), (AE, BB), (AE, BE)\}$, where (AE, BB) refers to an individual who

is randomly chosen from the non-responder arm of the regime $d^{(1)}$ and the other individual is randomly chosen from the responder arm of the regime $d^{(3)}$. Intuitively, $\hat{\eta}_{d^{(3)},d^{(1)}}^{\text{DP}}$ is the ratio of the weighted sum of the concordances to the weighted sum of the discordances. Here, the weight is a product of the number of times each of the selected two individuals in the pair is randomized. For example, if the pair is coming from (AE, BB) , the weight is 2×1 because the individual from the regime $d^{(1)}$ is a non-responder and hence randomized twice whereas the other individual from the regime $d^{(3)}$ is a responder and hence randomized only once in the study. Giving a higher weight to a non-responder makes sense in order to account for the structural imbalance between responders and non-responders inherently present in the “restricted” SMART design considered here (Figure 1) (Robins, 1997; Murphy, 2005; Nahum-Shani et al., 2012a). However, for the “unrestricted” SMART design (Collins, 2018) where both responders and non-responders are evenly randomized (See Supplementary Material Figure 1), no such weighting is necessary. The use of the notion of concordance in the DTR literature is not new; see Fan et al. (2017) and Liang et al. (2018) for concordance-assisted learning for optimal treatment regimes.

5.2. $dGOR$ for continuous outcome based on U -statistic

As mentioned in Section 2.1, Remark 1, $dGOR$ can also be defined for continuous outcomes. Specifically, we can write the $dGOR$ defined in (1) to compare the regimes $d^{(3)}$ and $d^{(1)}$ in a SMART with continuous outcome as

$$\eta_{d^{(3)},d^{(1)}} = \frac{P(Y_{d^{(3)}} > Y_{d^{(1)}})}{1 - P(Y_{d^{(3)}} > Y_{d^{(1)}})},$$

Note that, the $P(Y_g > Y_{g'})$ can be estimated by using the U -statistic

$$\frac{1}{n_{d^{(3)}}n_{d^{(1)}}} \sum_{s=1}^{n_{d^{(3)}}} \sum_{u=1}^{n_{d^{(1)}}} \phi(Y_{d^{(3)}_s}; Y_{d^{(1)}_u}), \quad (9)$$

where $n_{d^{(3)}}$ and $n_{d^{(1)}}$ denote the total number of people with treatment sequences consistent with the regimes $d^{(3)}$ and $d^{(1)}$, respectively; $Y_{d^{(3)}_s}$ denotes the primary outcome of s^{th} individual corresponding to the regime $d^{(3)}$; and

$$\begin{aligned} \phi(Y_{d^{(3)}_s}; Y_{d^{(1)}_u}) &= \sum_{R_B, R_A \in \{0,1\}} \gamma_A^{R_A} \gamma_B^{R_B} (1 - \gamma_A)^{1-R_A} (1 - \gamma_B)^{1-R_B} \\ &\quad \times I(Y_{B B^{R_B} E^{1-R_B}, s} > Y_{A A^{R_A} E^{1-R_A}, u}), \end{aligned} \quad (10)$$

where $I(\cdot)$ is an indicator function; $Y_{B E, s}$ denotes the primary outcome of s^{th} individual with responder status $R_B = 0$ (i.e., $(T_1, T_2) = (B, E)$) corresponding to the regime $d^{(3)}$. The U -statistic in (9) is a multi-sample U -statistic with $E(\phi(Y_{d^{(3)}_s}; Y_{d^{(1)}_u})) = P(Y_{d^{(3)}} > Y_{d^{(1)}})$ and $\phi(\cdot; \cdot)$ is symmetric by default as it contains only one argument from each of the two samples (Lehmann, 1998).

6. PRIMARY ANALYSIS AND SAMPLE SIZE FORMULA

Specifying a primary analysis is necessary for a SMART in order to power it (Murphy, 2005). In the present context, we first consider the primary analysis to test if the regime $d^{(3)}$ differs from the regime $d^{(1)}$ in terms of the ordinal primary outcome (comparison of distinct-path embed-

ded regimes). Consider the null hypothesis as $H_0 : \log \eta_{d^{(3)}, d^{(1)}}^{\text{DP}} = 0$ vs $H_1 : \log \eta_{d^{(3)}, d^{(1)}}^{\text{DP}} = \delta$, or equivalently $H_0 : \eta_{d^{(3)}, d^{(1)}}^{\text{DP}} = 1$ against the alternative hypothesis $H_1 : \eta_{d^{(3)}, d^{(1)}}^{\text{DP}} = e^\delta$, where δ could take any positive or negative value. Using the asymptotic distribution of $\log(\hat{\eta}_{d^{(3)}, d^{(1)}}^{\text{DP}})$ in (4) we use $\log(\hat{\eta}_{d^{(3)}, d^{(1)}}^{\text{DP}})$ as the test statistics for the primary analysis. For a positive (negative) value of δ , the high positive (negative) value of $\log(\hat{\eta}_{d^{(3)}, d^{(1)}}^{\text{DP}})$ is an indicator of departure from the null hypothesis. Let $z_{\alpha/2}$ be the $(1 - \alpha/2)$ percentile of the standard normal distribution and set the power of the test as $1 - \beta$, where β is the type-II error. Using (4) the required sample size is given by

$$N = (z_{\alpha/2} + z_\beta)^2 \frac{\sigma_{d^{(3)}, d^{(1)}}^2}{\delta^2}. \quad (11)$$

Here N is the total number of patients in the trial. We can consider $\delta/\sigma_{d^{(3)}, d^{(1)}}$ as the standardized effect size, which can potentially be elucidated from scientific investigators prior to designing the SMART.

The primary analysis and the sample size formula for the shared-path setup are similar to the above with replacement of $\log \eta_{d^{(3)}, d^{(1)}}^{\text{DP}}$ and $\sigma_{d^{(3)}, d^{(1)}}^2$ by $\log \eta_{d^{(2)}, d^{(1)}}^{\text{SP}}$ and $\sigma_{d^{(2)}, d^{(1)}}^2$, respectively.

7. EXTENSION TO K-STAGE SMART

The proposed methodology can be extended to a K -stage SMART, for $K > 2$. Here, for generality, we assume $K \geq 2$. In general, a K -stage DTR is of the form $g = (g_1, \dots, g_K)$ where g_k is the treatment decision at stage k ($k = 1, \dots, K$). Then the potential outcome under the regime g is

$$Y_g = \sum_{(t_1, \dots, t_K)} Y_{t_1, \dots, t_K} I\{g_1(H_1) = t_1, \dots, g_K(H_K) = t_K\},$$

where Y_{t_1, \dots, t_K} is the potential outcome under the treatment sequence (t_1, \dots, t_K) .

Following the same structure as in Figure 1, we can postulate a K -stage SMART that starts with two initial treatments A_1 or B_1 . For simplicity of notation, we will only discuss the comparison of two distinct-path regimes. Comparison of two shared-path regimes in a K -stage setup can be addressed similarly. Suppose in the regime g' , a patient starts with the initial treatment A_1 , continues the same treatment A_{k-1} at the k^{th} ($k = 2, \dots, K$) stage if s/he is a responder or switches to the treatment A_k if s/he is a non-responder to the previous stage treatment. Similarly in the regime g , suppose a patient starts with the initial treatment B_1 , continues the same treatment B_{k-1} at the k^{th} ($k = 2, \dots, K$) stage if s/he is a responder or switches to the treatment B_k if s/he is a non-responder to the previous stage treatment. Define the response rates after getting treatment A_k and B_k as γ_{A_k} and γ_{B_k} , respectively for $k = 1, \dots, K - 1$; corresponding response indicators are R_{A_k} and R_{B_k} , respectively. Let $Y_g(K)$ and $Y_{g'}(K)$ be the potential

outcomes for regimes g and g' , respectively. Similar to Section 3.1, here we have

$$\begin{aligned}
& P(Y_g(K) > Y_{g'}(K)) \\
= & \sum_{\substack{R_{A_1}, \dots, R_{A_{k'}} \in \{0,1\} \\ R_{B_1}, \dots, R_{B_k} \in \{0,1\} \\ k', k=2, \dots, K}} \sum_{u=1}^{J-1} \sum_{s=u+1}^J \left\{ \gamma_{A_{k'-1}}^{R_{A_{k'-1}}} (1 - \gamma_{A_{k'-1}})^{1-R_{A_{k'-1}}} \right. \\
& \quad \left. \times (1 - \gamma_{A_{k'-2}}) \cdots (1 - \gamma_{A_1}) \right\} \\
& \quad \times \left\{ \gamma_{B_{k-1}}^{R_{B_{k-1}}} (1 - \gamma_{B_{k-1}})^{1-R_{B_{k-1}}} (1 - \gamma_{B_{k-2}}) \cdots (1 - \gamma_{B_1}) \right\} \\
& \quad \times \pi_{\underline{A}_{k'-1}, u} \pi_{\underline{B}_{k-1}, s}, \tag{12}
\end{aligned}$$

and

$$\begin{aligned}
& P(Y_g(K) < Y_{g'}(K)) \\
= & \sum_{\substack{R_{A_1}, \dots, R_{A_{k'}} \in \{0,1\} \\ R_{B_1}, \dots, R_{B_k} \in \{0,1\} \\ k', k=2, \dots, K}} \sum_{u=2}^J \sum_{s=1}^{u-1} \left\{ \gamma_{A_{k'-1}}^{R_{A_{k'-1}}} (1 - \gamma_{A_{k'-1}})^{1-R_{A_{k'-1}}} \right. \\
& \quad \left. \times (1 - \gamma_{A_{k'-2}}) \cdots (1 - \gamma_{A_1}) \right\} \\
& \quad \times \left\{ \gamma_{B_{k-1}}^{R_{B_{k-1}}} (1 - \gamma_{B_{k-1}})^{1-R_{B_{k-1}}} (1 - \gamma_{B_{k-2}}) \cdots (1 - \gamma_{B_1}) \right\} \\
& \quad \times \pi_{\underline{A}_{k'-1}, u} \pi_{\underline{B}_{k-1}, s}, \tag{13}
\end{aligned}$$

where

$$\begin{aligned}
\pi_{\underline{B}_{k-1}, s} = & \pi_{B_1 B_1^{R_{B_1}} B_2^{1-R_{B_1}} B_2^{(1-R_{B_1}) R_{B_2}} B_3^{(1-R_{B_1})(1-R_{B_2})} \dots} \\
& B_{k-1}^{(1-R_{B_1}) \cdots (1-R_{B_{k-1}}) R_{B_{k-1}} B_k^{(1-R_{B_1}) \cdots (1-R_{B_{k-1}})(1-R_{B_{k-1}})}, s
\end{aligned}$$

denotes the s^{th} cell probability of a responder or non-responder after k^{th} stage for $(1 - R_{B_1}) \cdots (1 - R_{B_{k-1}}) R_{B_{k-1}} = 1$ or $(1 - R_{B_1}) \cdots (1 - R_{B_{k-1}})(1 - R_{B_{k-1}}) = 1$, respectively. Similarly, $\pi_{\underline{A}_{k'-1}, u}$ is also defined. Thus we define the K -stage $dGOR$, for $K \geq 2$, to compare two distinct-path regimes g with g' as

$$\eta_{g, g'}^{DP(K)} = \frac{P(Y_g(K) > Y_{g'}(K))}{P(Y_g(K) < Y_{g'}(K))}. \tag{14}$$

Note that, when $K = 2$, the above $dGOR$, $\eta_{g, g'}^{DP(K)}$ boils down to $\eta_{d^{(3)}, d^{(1)}}^{DP}$ with $g = 3$ and $g' = 1$ as defined in (2). The asymptotic variance of $\log(\hat{\eta}_{g, g'}^{DP(K)})$ is given by $N^{-1} \sigma_{g, g'}^2(K)$ (See appendix).

8. FINDING AN OPTIMAL DTR WITHIN A FINITE CLASS USING $dGOR$

So far in the current article, we have focused on comparing embedded regimes within a SMART. Now we illustrate how the concept of $dGOR$, coupled with a *policy search* approach,

can potentially help to find an optimal DTR within a finite class (Zhao et al., 2012, 2015a,b; Zhang et al., 2012; Laber et al., 2018).

Consider a finite class of regimes $\mathcal{G} = \{g^{(1)}, g^{(2)}, \dots, g^{(m)}\}$, where each member regime $g^{(m)}$, $m = 1, \dots, M$, consists of K decision rules corresponding to K stages of intervention, $g^{(m)} = (g_1^{(m)}, \dots, g_K^{(m)})$. Utilizing previously explained notations, the potential outcome $Y_{g^{(m)}}$ can be written as

$$Y_{g^{(m)}} = \sum_{(t_1, \dots, t_K)} Y_{t_1, \dots, t_K} I\{g_1^{(m)}(H_1) = t_1, \dots, g_K^{(m)}(H_K) = t_K\}.$$

Then the $dGOR$ between two member regimes $g^{(m)}$ and $g^{(m')}$ can be defined as

$$\eta_{g^{(m)}, g^{(m')}} = \frac{P(Y_{g^{(m)}} > Y_{g^{(m')}})}{P(Y_{g^{(m)}} < Y_{g^{(m')}})}. \quad (15)$$

Once we define the $dGOR$ s between any pair of regimes $(g^{(m)}, g^{(m')})$, we can apply some policy search method to find $g^{opt} \in \mathcal{G}$. In the following, we present a basic algorithm to illustrate the idea.

- 1: Initialize $g^{opt} \leftarrow g^{(1)}$, $\mathcal{G}_{search} = \mathcal{G} - \{g^{(1)}\}$
- 2: **If** $\eta_{g^{opt}, g^{(2)}} > 1$ significantly, **then** $\mathcal{G}_{search} = \mathcal{G}_{search} - \{g^{(2)}\}$
else $\mathcal{G}_{search} = \mathcal{G}_{search} - \{g^{(2)}\}$ and $g^{opt} \leftarrow g^{(2)}$
- 3: **If** $\eta_{g^{opt}, g^{(3)}} > 1$ significantly, **then** $\mathcal{G}_{search} = \mathcal{G}_{search} - \{g^{(3)}\}$
else $\mathcal{G}_{search} = \mathcal{G}_{search} - \{g^{(2)}\}$ and $g^{opt} \leftarrow g^{(3)}$
- 4: Continue till $\mathcal{G}_{search} = \emptyset$, the empty set.

Output: g^{opt}

Note that since decisions at each step are based on hypothesis testing, one should adjust for multiple testing, e.g. via Bonferroni correction.

9. SIMULATION STUDIES

In this section, we present two thorough simulation studies to illustrate the performance of the methodologies proposed above. Specifically, Section 9.1 presents the performance of the $dGOR$ -based estimation and inference in case of distinct-path dynamic regimes (cf. Section 3); Section 9.2 involves the performance of $dGOR$ in case of shared-path dynamic regimes (cf. Section 4); Section 9.3 illustrates performance of $dGOR$ in few scenarios where one or more arms (responder or non-responder) of the two regimes contain some small cell probabilities. **The details of the data generation process have been described in *Supplementary Material*.** The response rates corresponding to initial treatments A and B are taken as $\gamma_A = 0.3$ and $\gamma_B = 0.4$, respec-

tively. **Simulations considering different values of response rates are shown in Supplementary Material.** We assume the type-I error rate as 0.05 and the nominal power as 0.80.

9.1. Simulation study for distinct-path regimes

This study aims to assess the performance of $\eta_{d^{(3)},d^{(1)}}^{\text{DP}}$ in comparing two distinct-path embedded regimes $d^{(1)}$ and $d^{(3)}$. We consider an ordinal outcome with $J = 3$ categories in ascending order. For regime $d^{(1)}$, the cell probabilities of the primary outcome are given by $\pi(A, A) = (\pi_{AA,1}, \pi_{AA,2}, 1 - \pi_{AA,1} - \pi_{AA,2})$ for the responders and $\pi(A, E) = (\pi_{AE1}, \pi_{AE2}, 1 - \pi_{AE1} - \pi_{AE2})$ for the non-responders. Likewise, for regime $d^{(3)}$, the corresponding cell probabilities are $\pi(B, B) = (\pi_{BB1}, \pi_{BB2}, 1 - \pi_{BB1} - \pi_{BB2})$ for the responders and $\pi(B, E) = (\pi_{BE1}, \pi_{BE2}, 1 - \pi_{BE1} - \pi_{BE2})$ for the non-responders. The serial number (SL) in the first column of Table 1 shows the six different scenarios. The first three of them correspond to $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} > 1$ and the last three correspond to $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} < 1$. Here $\eta_{d^{(3)},d^{(1)}}^{\text{DP}}$ denotes the true values of corresponding population $dGOR$. We obtain the true value of $dGOR$ ($\eta_{d^{(3)},d^{(1)}}^{\text{DP}}$) by using Monte Carlo computation considering a ‘large’ population of size of 10^6 . Figure 2(a) shows the plot of barycentric coordinates of the probabilities from the six different scenarios in Table 1 (Jupp et al., 2012). Any three probabilities of the form $(p_1, p_2, 1 - p_1 - p_2)$ can be represented by a unique point in an equilateral triangle in a barycentric coordinate system. Three vertices are denoted by $(1, 0, 0)$, $(0, 1, 0)$ and $(0, 0, 1)$. In a barycentric coordinate plot, a point $(p_1, p_2, 1 - p_1 - p_2)$ can be located by considering i) a distance p_1 from the opposite arm of the vertex $(1, 0, 0)$, ii) a distance p_2 from the opposite arm of the vertex $(0, 1, 0)$, and, iii) a distance $1 - p_1 - p_2$ from the opposite arm of the vertex $(0, 0, 1)$. The objective of the Figure 2(a) is to show how the six simulation scenarios in Table 1 are distributed in the barycentric coordinate system.

In Table 1, the ‘Std. ES’ denotes the standardized effect size which is calculated as $\log \eta_{d^{(3)},d^{(1)}}^{\text{DP}}$ divided by the square root of the variance of $\log \eta_{d^{(3)},d^{(1)}}^{\text{DP}}$; N denotes the estimated sample size. Based on the 5,000 simulations, $\hat{\eta}_{d^{(3)},d^{(1)}}^{\text{DP}}$ is the estimated value of $\eta_{d^{(3)},d^{(1)}}^{\text{DP}}$; SSE is the sample standard error; ASE is the asymptotic standard error; \widehat{power} is the estimated power and \widehat{CP} is the estimated coverage probability. In Table 1, $\hat{\eta}_{d^{(3)},d^{(1)}}^{\text{DP}}$ is close to its true value in all the six scenarios, indicating good estimation. The estimated sample size N varies from 164 to 571 when $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} > 1$ and from 305 to 1096 when $\eta_{d^{(3)},d^{(1)}}^{\text{DP}} < 1$. Note that, N is a decreasing function of the absolute value of the standardized effect size. However, we can have the same standardized effect size for different combinations of $\eta_{d^{(3)},d^{(1)}}^{\text{DP}}$, the response rates and the cell probabilities corresponding to the two regimes. The SSE and ASE are close to each other in all the scenarios. The estimated empirical powers and the coverage probabilities are close to their corresponding nominal values in all the cases.

9.2. Simulation study for shared-path regimes

In this section we consider the simulation study to compare the shared-path regimes $d^{(1)}$ and $d^{(2)}$ that start with the same initial treatments, as discussed in the section 4. Similar to the previous section, here also, we set the number of categories of the ordinal outcome variable as $J = 3$ in ascending order. For regime $d^{(2)}$, the cell probabilities of primary outcome are given by $\pi(A, A) = (\pi_{AA,1}, \pi_{AA,2}, 1 - \pi_{AA,1} - \pi_{AA,2})$ for the responders and $\pi(A, F) =$




Fig. 2: Corresponding to Tables 1 and 2, the Barycentric plots of different multinomial probabilities for comparing (a) distinct-path regimes, \bullet : $\pi(A, A)$, \bullet : $\pi(A, E)$, \bullet : $\pi(B, B)$, \bullet : $\pi(B, E)$; and (b) shared-path regimes, \bullet : $\pi(A, A)$, \bullet : $\pi(A, E)$, \bullet : $\pi(A, F)$.

Table 1: Comparison of Distinct-path regimes with ordinal outcome. Here, $\gamma_A = 0.3$ and $\gamma_B = 0.4$, nominal power is 0.80 and type-I is 0.05. The standardized effect size is in log-scale. Estimated power and coverage probability are based on 5,000 simulations.

SL	$\pi(A, A)$ $\pi(A, E)$	$\pi(B, B)$ $\pi(B, E)$	Std. ES ² (log scale)	$\eta_{d^{(3)}, d^{(1)}}^{DP}$	N	$\hat{\eta}_{d^{(3)}, d^{(1)}}^{DP}$	SSE	ASE	\widehat{power}	\widehat{CP}
1	(0.23, 0.51, 0.26) (0.50, 0.41, 0.09)	(0.31, 0.50, 0.19) (0.14, 0.47, 0.39)	0.219	2.55	164	2.72	1.06	1.14	0.78	0.94
2	(0.41, 0.23, 0.36) (0.58, 0.20, 0.22)	(0.50, 0.22, 0.28) (0.27, 0.22, 0.51)	0.147	1.86	366	1.89	0.43	0.43	0.78	0.95
3	(0.21, 0.40, 0.39) (0.30, 0.41, 0.29)	(0.28, 0.41, 0.31) (0.12, 0.34, 0.54)	0.117	1.64	571	1.66	0.29	0.30	0.79	0.95
4	(0.13, 0.22, 0.65) (0.09, 0.18, 0.73)	(0.10, 0.19, 0.71) (0.20, 0.26, 0.54)	-0.085	0.66	1096	0.67	0.10	0.10	0.78	0.95
5	(0.12, 0.24, 0.64) (0.07, 0.18, 0.75)	(0.09, 0.21, 0.70) (0.18, 0.28, 0.54)	-0.099	0.61	797	0.61	0.12	0.11	0.82	0.95
6	(0.28, 0.52, 0.20) (0.08, 0.43, 0.49)	(0.34, 0.50, 0.16) (0.20, 0.52, 0.28)	-0.161	0.50	305	0.53	0.26	0.16	0.81	0.94

$(\pi_{AF,1}, \pi_{AF,2}, 1 - \pi_{AF,1} - \pi_{AF,2})$ for the non-responders. Note that, $\pi(A, A)$ corresponds to both regimes $d^{(1)}$ and $d^{(2)}$ (shared-path). The barycentric coordinate plot in Figure 2(b) shows how the six simulation scenarios in Table 2 are distributed in the barycentric coordinate system.

Table 2 shows the results of six scenarios for shared-path comparison of two regimes. Similar to previous section, the first three scenarios correspond to $\eta_{d^{(2)}, d^{(1)}}^{SP} > 1$ and the last three scenarios to $\eta_{d^{(2)}, d^{(1)}}^{SP} < 1$. The estimated sample size N ranges from 304 to 659 when $\eta_{d^{(2)}, d^{(1)}}^{SP} > 1$ and from 241 to 1218 when $\eta_{d^{(2)}, d^{(1)}}^{SP} < 1$. In all the six scenarios, the SSE and the ASE are close

Table 2: Comparison of Shared-path regimes with ordinal outcome. Here, $\gamma_A = 0.3$ and $\gamma_B = 0.4$, nominal power is 0.80 and type-I is 0.05. The standardized effect size is in log-scale. Estimated power and coverage probability are based on 5,000 simulations.

SL	$\pi(A, A)$ $\pi(A, E)$	$\pi(A, F)$	Std. ES (log scale)	$\eta_{d^{(2)}, d^{(1)}}^{SP}$	N	$\hat{\eta}_{d^{(2)}, d^{(1)}}^{SP}$	SSE	ASE	\widehat{power}	\widehat{CP}
1	(0.24, 0.52, 0.24) (0.63, 0.33, 0.04)	(0.38, 0.49, 0.13)	0.161	1.88	304	1.94	0.44	0.49	0.77	0.97
2	(0.03, 0.66, 0.31) (0.19, 0.74, 0.07)	(0.07, 0.75, 0.18)	0.148	1.96	357	1.97	0.54	0.51	0.77	0.94
3	(0.43, 0.17, 0.40) (0.73, 0.12, 0.15)	(0.56, 0.16, 0.28)	0.109	1.56	659	1.60	0.26	0.27	0.81	0.96
4	(0.36, 0.36, 0.28) (0.40, 0.35, 0.25)	(0.52, 0.32, 0.16)	-0.080	0.73	1218	0.73	0.08	0.09	0.80	0.95
5	(0.17, 0.10, 0.73) (0.15, 0.10, 0.75)	(0.29, 0.13, 0.58)	-0.113	0.58	618	0.58	0.12	0.12	0.82	0.94
6	(0.24, 0.35, 0.41) (0.16, 0.32, 0.52)	(0.38, 0.35, 0.27)	-0.181	0.50	241	0.50	0.13	0.14	0.80	0.96

to each other. The estimated empirical powers and the coverage probabilities are close to their corresponding nominal values.

In summary, from both the simulation studies in Sections 9.1 and 9.2, it is evident that the proposed $dGORs$ for comparing both distinct-path and shared-path regimes perform well.

9.3. Simulation study with smaller cell probabilities

In general, the maximum likelihood estimate of a small cell probability (say less than 5%) may end up with large bias due to less number of individuals in that cell. These biases in estimated cell probabilities make the corresponding estimated power and CP to deviate from their nominal values. Note that, the estimation problem related to a small probability/frequency is well known in the inference of categorical data (Yates, 1934; Agresti, 1990). In Table 3, we have considered similar scenarios to explore how our methodologies work. In all the five scenarios of Table 3, some of the cell probabilities are less than 5% or close to it. In Figures 3(a) and (b), we have shown how the five simulation scenarios from Table 3 are distributed in the barycentric coordinate system.

The estimated power and CP deviate from their respective values. In scenario 1 for distinct-path comparison, the estimated value of $dGOR$ is almost same as the population $dGOR$. As expected, the estimated power and CP are not much less than their nominal values. However, in all the other four scenarios, either power or CP or both are far apart from their respective nominal values. The estimated power is 0.39 in scenario 3 of distinct-path comparison where the last two cell probabilities of $\pi(A, E)$ are 0.03 and 0.02, respectively. In summary, when the cell probabilities of some cells corresponding to a regime become less than 5%, the estimated $dGOR$ should be interpreted with caution.

Table 3: Some examples with small cell probabilities. Here, $\gamma_A = 0.3$ and $\gamma_B = 0.4$, nominal power is 0.80 and type-I is 0.05. The standardized effect size is in log-scale. Estimated power and coverage probability are based on 5,000 simulations.

SL	$\pi(A, A)$ $\pi(A, E)$	$\pi(B, B)$ $\pi(B, E)$	Std. ES (log scale)	$\eta_{d(3),d(1)}^{DP}$	N	$\hat{\eta}_{d(3),d(1)}^{DP}$	SSE	ASE	\widehat{power}	\widehat{CP}
Comparison of distinct-path:										
1	(0.04, 0.87, 0.09) (0.06, 0.88, 0.06)	(0.07, 0.88, 0.05) (0.02, 0.82, 0.16)	0.072	1.68	1506	1.67	0.39	0.32	0.77	0.92
2	(0.06, 0.55, 0.39) (0.02, 0.40, 0.58)	(0.04, 0.49, 0.47) (0.12, 0.63, 0.26)	-0.156	0.48	322	1.73	2.63	3.29	0.79	0.56
3	(0.81, 0.11, 0.08) (0.95, 0.03, 0.02)	(0.87, 0.08, 0.05) (0.69, 0.16, 0.15)	0.170	3.23	272	3.63	2.06	10.7	0.39	0.97
Comparison of Shared-path:										
	$\pi(A, A)$ $\pi(A, E)$	$\pi(A, F)$		$\eta_{d(2),d(1)}^{SP}$		$\hat{\eta}_{d(2),d(1)}^{SP}$				
1	(0.03, 0.82, 0.15) (0.19, 0.79, 0.02)	(0.06, 0.86, 0.08)	0.137	2.23	420	2.16	0.74	0.71	0.74	0.87
2	(0.06, 0.47, 0.47) (0.02, 0.33, 0.65)	(0.12, 0.57, 0.31)	-0.219	0.38	164	1.87	1.43	1.16	0.74	0.43




Fig. 3: Corresponding to Table 3, the Barycentric plots of different multinomial probabilities for comparing (a) distinct-path, \bullet : $\pi(A, A)$, \bullet : $\pi(A, E)$, \bullet : $\pi(B, B)$, \bullet : $\pi(B, E)$; and (b) shared-path regimes, \bullet : $\pi(A, A)$, \bullet : $\pi(A, E)$, \bullet : $\pi(A, F)$.

10. APPLICATION TO STAR*D DATA

In this section, we demonstrate how the developed $dGOR$ can be used to compare any two different embedded regimes in a two-stage SMART for treating depressive disorder based on STAR*D data. In this study, there were four stages/levels of intervention, with a total sample size of 4041. For illustration purpose, we have not considered level 4 of the STAR*D in the cur-

rent analysis. We consider the data from level 1 as the baseline characteristics since in this level all the patients were given citalopram (CIT) without any randomization. Symptom severity was measured by quick inventory of depressive symptomatology (QIDS) score. At every level, patients who had QIDS less than or equal to 5 were considered responders, only the non-responders were eligible to enter the next level of the study. The non-responders at the end of level 1 entered level 2 where they were randomized to either (a) *mono therapy*, denoted as ‘ M ’, which includes: bupropion – sustained release (BUP-SR) or sertraline (SER) or venlafaxine – extended release (VEN-XR) or cognitive psychotherapy (CT); or (b) *combination therapy*, denoted as ‘ C ’, which includes: CIT + BUP-SR, or CIT+ bupirone (BUS), or CIT + CT. Patients who were given CT or CIT+CT at level 2 and who had non-satisfactory response were eligible to enter a supplementary level 2A with treatment options VEN-XR or BUP-SR. Patients not responding satisfactorily at level 2 (and level 2A, if applicable) would continue to level 3, where for randomization, the mono therapy options were mirtazapine (Mirt) or nortriptyline (NTP), whereas the combination therapy options were either lithium (Li) or thyroid hormone (Thy) combined with treatments given at the previous level. In this analysis, we consider the levels 2 and 2A as a single level. In other words, a patient who entered level 2A is considered to have obtained combination therapy. We rename the level 2 + 2A as stage 1 and level 3 as stage 2 (Chakraborty et al., 2016). Note that, in STAR*D, the responders did not receive any treatment, but they were followed for 12 months (Rush et al., 2004). In summary, for the analysis considered here from the STAR*D study, at the first stage, patients were randomized between mono or combination therapies, the responders from stage 1 were followed for 12 months and the non-responders were re-randomized between mono or combination therapies at the second stage. In other words, the data setup from STAR*D is consistent with Figure 1.

In Section 1, we have considered four embedded regimes based on Figure 1. Given the above setup, the four embedded regimes in the STAR*D study are $(M, FU^{R_M} M^{1-R_M})$, $(M, FU^{R_M} C^{1-R_M})$, $(C, FU^{R_C} M^{1-R_C})$, and $(C, FU^{R_C} C^{1-R_C})$, where FU denotes 12 months follow up for responders and R_M and R_C are the responder statuses (1 = responder and 0 = non-responder). The outcome of interest is the quality of life (QOL), an ordinal variable with the levels 1 (very poor), 2 (poor), 3 (fair), 4 (good), and 5 (very good). In each stage, the outcome data (QOL) were recorded only for the non-responders from the previous-stage (Chakraborty et al., 2016). Following Chakraborty & Moodie (2013), we consider the overall QOL for each subject as

$$Y = RY_1 + (1 - R) \left(\frac{Y_1 + Y_2}{2} \right), \quad (16)$$

where Y_1 and Y_2 are the QOL at the end of stages 1 and 2, respectively, $R \in \{R_M, R_C\}$. From the five categories of QOL in STAR*D and using (16), for the illustration purpose, we construct three new categories of QOL as poor ($Y < 3$), fair ($Y = 3$) and good ($Y > 3$). An analysis considering four categories of the QOL is described in the [Supplementary Material](#).

In Table 4, we have shown the different comparison of regimes from STAR*D data. Note that, there are four different pairs of distinct-path regimes and two different pairs of shared-path regimes. Among the first four comparison of distinct-path regimes in Table 4, only the first two have statistically significant $dGOR$ (confidence intervals (CIs) of the corresponding log of $dGOR$ do not contain 0). Based on these $dGORs$, one can infer that giving combination ther-

apies (C) at both stages or at least switch to monotherapy (M) at the second stage are better options than giving monotherapies at both stages. On the other hand, among the two different shared-path comparisons in the last two entries of Table 4, only the first one is statistically significant (with respect to log of $dGOR$). In other words, we can conclude that it is better to switch to combination therapy (C) for a patient who is a non-responder after having monotherapy (M) at the first stage.

Table 4: Comparison of regimes with quality of life (QOL) as the ordinal outcome in STAR*D data. Here, M : monotherapy, C : combination therapy and FU : follow up. The response rates are $\gamma_M = 0.32$ and $\gamma_C = 0.45$, following the first-stage treatment M and C respectively. Note that, $dGOR_{2,1} = P(Y_{Regime(2)} > Y_{Regime(1)})/P(Y_{Regime(2)} < Y_{Regime(1)})$.

$Regime^{(1)}$	$Regime^{(1)}$.prob: (Responder) (Non-Responder)	$Regime^{(2)}$	$Regime^{(2)}$.prob: (Responder) (Non-Responder)	$dGOR_{2,1}$	$\log.dGOR_{2,1}$	CI.log. $dGOR_{2,1}$
Comparison of distinct-path regimes						
$(M, FU^{R_M} M^{1-R_M})$	(0.08, 0.33, 0.59) (0.50, 0.34, 0.16)	$(C, FU^{R_C} M^{1-R_C})$	(0.10, 0.30, 0.60) (0.41, 0.39, 0.20)	1.43	0.36	(0.06, 0.66)
$(M, FU^{R_M} M^{1-R_M})$	(0.08, 0.33, 0.59) (0.50, 0.34, 0.16)	$(C, FU^{R_C} C^{1-R_C})$	(0.10, 0.30, 0.60) (0.46, 0.32, 0.21)	1.36	0.31	(0.01, 0.61)
$(M, FU^{R_M} C^{1-R_M})$	(0.08, 0.33, 0.59) (0.39, 0.25, 0.36)	$(C, FU^{R_C} M^{1-R_C})$	(0.10, 0.30, 0.60) (0.41, 0.39, 0.20)	0.92	-0.08	(-0.39, 0.23)
$(M, FU^{R_M} C^{1-R_M})$	(0.08, 0.33, 0.59) (0.39, 0.25, 0.36)	$(C, FU^{R_C} C^{1-R_C})$	(0.10, 0.30, 0.60) (0.46, 0.32, 0.21)	0.89	-0.11	(-0.43, 0.20)
Comparison of shared-path regimes						
$(M, FU^{R_M} M^{1-R_M})$	(0.08, 0.33, 0.59) (0.50, 0.34, 0.16)	$(M, FU^{R_M} C^{1-R_M})$	(0.08, 0.33, 0.59) (0.39, 0.25, 0.36)	1.52	0.42	(0.07, 0.77)
$(C, FU^{R_C} M^{1-R_C})$	(0.10, 0.30, 0.60) (0.41, 0.39, 0.20)	$(C, FU^{R_C} C^{1-R_C})$	(0.10, 0.30, 0.60) (0.46, 0.32, 0.21)	0.96	-0.04	(-0.30, 0.22)

11. DISCUSSION

The dynamic generalized odds-ratio ($dGOR$) is a powerful measure of association. It is suitable for binary, ordinal and continuous outcomes related to SMART studies. Simple odds-ratio (OR) is widely used in clinical and behavioral sciences because it is easy to interpret. We suspect that the use of $dGOR$ to compare two DTRs can make SMART design more popular among practitioners. A freely available online tool (<https://sites.google.com/site/palashghoshstat/sample-size-calculator>) using R statistical software is provided to make the proposed method accessible to other researchers.

In this work, we have considered a SMART that starts with randomization of two initial treatments (A and B), and there are two available treatment options (e.g., E and F) at each of the other randomization nodes. The same is also true for the K -stage SMART discussed in Section 7. The $dGOR$ defined in this article can, in principle, also work in a SMART with more than two treatment options at any stage.

The responders from the first-stage of SMART described in Figure 1 are not randomized; instead they continue with the same treatment as in the previous stage. This type of SMARTs is called “restricted” SMART (Nahum-Shani et al., 2012a). However, there are “unrestricted” SMARTs where both responders and non-responders are re-randomized potentially to different treatments (Collins, 2018). We have described *dGOR* for an “unrestricted” SMART in the *Supplementary Material*.

We have briefly shown how the notion of *dGOR* can be used to compare arbitrary regimes, and thereby can be employed to find an optimal regime within a finite class via policy search. However, we have not studied any theoretical or computational properties of the policy search algorithm described. Such a study could be a worthwhile future research endeavour.

12. APPENDIX

12.1. Likelihood for two stage SMART

The ordinal primary outcome Y takes the values in ordered categories $1, \dots, J$ (higher the better). Let t_1 and t_2 be the observed values of T_1 and T_2 . Here we have

$$\begin{aligned} Y_{t_1 t_2} &= Y \times I\{T_1 = t_1, T_2 = t_2\} \\ \pi_{t_1 t_2, j} &= P(Y_{t_1 t_2} = j), \end{aligned} \quad (17)$$

such that $\sum_{j=1}^J \pi_{t_1 t_2, j} = 1$ for any (t_1, t_2) .

The likelihood function for the i^{th} patient who obtained the treatment sequence $(T_1 = t_1, T_2 = t_1)$ or $(T_1 = t_1, T_2 = t_2)$ (here, $t_1 \neq t_2$) with observed outcome denoted as $Y_i = j; j = 1, \dots, J$, can be written as

$$\begin{aligned} \mathcal{L}_i &= \left\{ \tau_{T_{1i}=t_1} \tau_{T_{2i}=t_1|T_{1i}=t_1} \gamma_{T_{1i}=t_1} \prod_{j=1}^{J-1} \pi_{t_1 t_1, j}^{I\{Y_i=j\}} \left(1 - \sum_{j=1}^{J-1} \pi_{t_1 t_1, j} \right)^{1 - \sum_{j=1}^{J-1} I\{Y_i=j\}} \right\}^{I\{T_{1i}=t_1, T_{2i}=t_1\}} \\ &\times \left\{ \tau_{T_{1i}=t_1} \tau_{T_{2i}=t_2|T_{1i}=t_1} (1 - \gamma_{T_{1i}=t_1}) \prod_{j=1}^{J-1} \pi_{t_1 t_2, j}^{I\{Y_i=j\}} \left(1 - \sum_{j=1}^{J-1} \pi_{t_1 t_2, j} \right)^{1 - \sum_{j=1}^{J-1} I\{Y_i=j\}} \right\}^{I\{T_{1i}=t_1, T_{2i}=t_2\}} \end{aligned} \quad (18)$$

where $\gamma_{T_{1i}=t_1}$ is the response rate after obtaining treatment $T_{1i} = t_1$ at the first stage; $I\{\cdot\}$ is an indicator function; $I\{T_{1i} = t_1, T_{2i} = t_1\} = 1$ denotes a responder and $I\{T_{1i} = t_1, T_{2i} = t_2\}$ denotes a non-responder; $\tau_{T_{1i}=t_1}$ is the randomization probability at the first stage, which can be taken as 0.5 under equal randomization at that stage, and $\tau_{T_{2i}=t_2|T_{1i}=t_1}$ denotes the same at the second stage. Note that, $\tau_{T_{2i}=t_1|T_{1i}=t_1}$ is 1 (for a responder); considering an equal randomization at the second stage, $\tau_{T_{2i}=t_2|T_{1i}=t_1} = 0.5$ for a non-responder. The complete likelihood (Thall et al., 2002) for all the N patients takes the form

$$\mathcal{L} = \prod_{i=1}^N \mathcal{L}_i. \quad (19)$$

The maximum likelihood estimates of $\pi_{t_1 t_2, j}$ and $\gamma_{T_1=t_1}$ from (19) can be written as

$$\hat{\pi}_{t_1 t_1, j} = \frac{\sum_{i=1}^N I\{T_{1i} = t_1, T_{2i} = t_1\} I\{Y_i = j\}}{\sum_{i=1}^N I\{T_{1i} = t_1, T_{2i} = t_1\}},$$

$$\text{for } t_1 \neq t_2, \hat{\pi}_{t_1 t_2, j} = \frac{\sum_{i=1}^N I\{T_{1i} = t_1, T_{2i} = t_2\} I\{Y_i = j\}}{\sum_{i=1}^N I\{T_{1i} = t_1, T_{2i} = t_2\}}, \text{ and,}$$

$$\hat{\gamma}_{t_1} = \frac{\sum_{i=1}^N I\{T_{1i} = t_1, T_{2i} = t_1\}}{\sum_{i=1}^N I\{T_{1i} = t_1\}},$$

respectively. Note that, the likelihood (19) does not consider any embedded regime structure; it is completely specified by the observed treatment sequences.

12.2. Asymptotic Distribution of $dGOR$ for distinct-path

Here we derive the asymptotic distribution of $\hat{\eta}_{d^{(3)}, d^{(1)}}^{\text{DP}}$ that compares two distinct-path regimes $d^{(1)}$ and $d^{(3)}$. From (2), we can write

$$\eta_{d^{(3)}, d^{(1)}}^{\text{DP}} = \frac{P(Y_{d^{(3)}} > Y_{d^{(1)}})}{P(Y_{d^{(3)}} < Y_{d^{(1)}})} = \frac{\Pi_{Nu}}{\Pi_{De}}.$$

The Π_{Nu} and Π_{De} are the numerator and the denominator of $\eta_{d^{(3)}, d^{(1)}}^{\text{DP}}$, respectively. Define $p_{AA^R A E^{1-R_A}, u}$ and $p_{BB^R B E^{1-R_B}, s}$ as the maximum likelihood estimates of $\pi_{AA^R A E^{1-R_A}, u}$ and $\pi_{BB^R B E^{1-R_B}, s}$ from the likelihood (19), respectively. Thus,

$$\sqrt{N}(\hat{\eta}_{d^{(3)}, d^{(1)}}^{\text{DP}} - \eta_{d^{(3)}, d^{(1)}}^{\text{DP}}) = \sqrt{N} \left[\frac{P_{Nu}}{P_{De}} - \frac{\Pi_{Nu}}{\Pi_{De}} \right] = \sqrt{N} \cdot \frac{P_{Nu}\Pi_{De} - P_{De}\Pi_{Nu}}{P_{De}\Pi_{De}}, \quad (20)$$

where P_{Nu} and P_{De} are the estimated version of Π_{Nu} and Π_{De} obtained by replacing corresponding π values with estimated p . For example, $\pi_{AA^R A E^{1-R_A}, u}$ is replaced by the $p_{AA^R A E^{1-R_A}, u}$. Note that, in this derivation, we treat response rates γ_A and γ_B as nuisance parameters and corresponding MLEs obtained from likelihood (19) can be used to plug-in the $dGOR$ expression. The expression (20) has an asymptotic distribution that is same with the asymptotic distribution of

$$\frac{1}{\Pi_{De}^2} \cdot \sqrt{N} \cdot [P_{Nu}\Pi_{De} - P_{De}\Pi_{Nu}], \quad (21)$$

using $P_{De} \rightarrow \Pi_{De}$ in probability (Goodman & Kruskal, 1963, 1972). Now, we need to find out the asymptotic distribution of

$$\sqrt{N} \cdot [P_{Nu}\Pi_{De} - P_{De}\Pi_{Nu}].$$

Using delta method, the above is asymptotically normal with mean zero and the asymptotic variance can be obtained as below. Note that, P_{Nu} and P_{De} both are function of p_{ab} , $a =$

$AA, AE, AF, BB, BE, BF; b = 1, \dots, J$. Thus,

$$\begin{aligned} \frac{\partial P_{Nu}}{\partial p_{ab}} &= \frac{\partial}{\partial p_{ab}} \sum_{R_A, R_B \in \{0,1\}} \sum_{s>u} \left\{ \gamma_A^{R_A} \gamma_B^{R_B} (1 - \gamma_A)^{1-R_A} (1 - \gamma_B)^{1-R_B} \right. \\ &\quad \left. \times p_{AA^{R_A} E^{1-R_A, u}} p_{BB^{R_B} E^{1-R_B, s}} \right\} \\ &= \begin{cases} 0 & \text{if } a = AF \text{ or } BF \\ \sum_{b>u} [(1 - \gamma_A)(1 - \gamma_B)p_{AE, u} + \gamma_A(1 - \gamma_B)p_{AA, u}] & \text{if } a = BE \\ \sum_{b>u} [(1 - \gamma_A)\gamma_B p_{AE, u} + \gamma_A \gamma_B p_{AA, u}] & \text{if } a = BB \\ \sum_{s>b} [(1 - \gamma_A)(1 - \gamma_B)p_{BE, s} + (1 - \gamma_A)\gamma_B p_{BB, s}] & \text{if } a = AE \\ \sum_{s>b} [\gamma_A(1 - \gamma_B)p_{BE, s} + \gamma_A \gamma_B p_{BB, s}] & \text{if } a = AA \end{cases} \\ &= I(a = AA) \sum_{s>b} \gamma_A [(1 - \gamma_B)p_{BE, s} + \gamma_B p_{BB, s}] \\ &\quad + I(a = AE) \sum_{s>b} (1 - \gamma_A) [(1 - \gamma_B)p_{BE, s} + \gamma_B p_{BB, s}] \\ &\quad + I(a = BB) \sum_{b>u} \gamma_B [(1 - \gamma_A)p_{AE, u} + \gamma_A p_{AA, u}] \\ &\quad + I(a = BE) \sum_{b>u} (1 - \gamma_B) [(1 - \gamma_A)p_{AE, u} + \gamma_A p_{AA, u}], \end{aligned}$$

where I is an indicator function. Similarly,

$$\begin{aligned} \frac{\partial P_{De}}{\partial p_{ab}} &= I(a = AA) \sum_{s<b} \gamma_A [(1 - \gamma_B)p_{BE, s} + \gamma_B p_{BB, s}] \\ &\quad + I(a = AE) \sum_{s<b} (1 - \gamma_A) [(1 - \gamma_B)p_{BE, s} + \gamma_B p_{BB, s}] \\ &\quad + I(a = BB) \sum_{b<u} \gamma_B [(1 - \gamma_A)p_{AE, u} + \gamma_A p_{AA, u}] \\ &\quad + I(a = BE) \sum_{b<u} (1 - \gamma_B) [(1 - \gamma_A)p_{AE, u} + \gamma_A p_{AA, u}]. \end{aligned}$$

Denote

$$P'_{ab}(Nu) = \left. \frac{\partial P_{Nu}}{\partial p_{ab}} \right|_{p_{ab}=\pi_{ab}}$$

and

$$P'_{ab}(De) = \left. \frac{\partial P_{De}}{\partial p_{ab}} \right|_{p_{ab}=\pi_{ab}}.$$

Hence, derivation of $P_{Nu}\Pi_{De} - P_{De}\Pi_{Nu}$ w.r.t p_{ab} and evaluated at π_{ab} is $\Pi_{De}P'_{ab}(Nu) - \Pi_{Nu}P'_{ab}(De)$. So, the asymptotic variance of $\sqrt{N} \cdot [P_{Nu}\Pi_{De} - P_{De}\Pi_{Nu}]$ is same as the asymp-

otic variance of

$$\sum_a \sum_b [\Pi_{De} P'_{ab}(Nu) - \Pi_{Nu} P'_{ab}(De)] \sqrt{N} \cdot (p_{ab} - \pi_{ab}), \quad (22)$$

(Goodman & Kruskal, 1963). Thus, the corresponding variance is

$$\begin{aligned} \sum_a \sum_b \sum_{a'} \sum_{b'} [\Pi_{De} P'_{ab}(Nu) - \Pi_{Nu} P'_{ab}(De)] [\Pi_{De} P'_{a'b'}(Nu) - \Pi_{Nu} P'_{a'b'}(De)] \\ \times \frac{1}{\omega_a} \delta_{aa'} [\delta_{bb'} \pi_{ab} - \pi_{ab} \pi_{a'b'}], \quad (23) \end{aligned}$$

where $\frac{1}{\omega_a} \delta_{aa'} [\delta_{bb'} \pi_{ab} - \pi_{ab} \pi_{a'b'}]$ is the variance of $\sqrt{N} \cdot (p_{ab} - \pi_{ab})$, $\delta_{kk'} = 1$ if $k = k'$, 0 otherwise and $\omega_a = N_a./N$, where $N_a.$ is the number of sample from a^{th} population.

In (23), four terms that involve $\delta_{bb'}$ are:

$$\sum_a \sum_b \frac{1}{\omega_a} \Pi_{De}^2 (P'_{ab}(Nu))^2 \pi_{ab} = \Pi_{De}^2 \Pi_{NuNu},$$

where Π_{NuNu}

$$\begin{aligned} = \sum_a \sum_b \frac{1}{\omega_a} \left(\sum_{s>b} [(1 - \gamma_B) \pi_{BE,s} + \gamma_B \pi_{BB,s}] [\gamma_A I(a = AA) + (1 - \gamma_A) I(a = AE)] \right. \\ \left. + \sum_{b>u} [(1 - \gamma_A) \pi_{AE,u} + \gamma_A \pi_{AA,u}] [\gamma_B I(a = BB) + (1 - \gamma_B) I(a = BE)] \right)^2 \pi_{ab}; \quad (24) \end{aligned} \quad (25)$$

$$- \sum_a \sum_b \frac{1}{\omega_a} \Pi_{Nu} \Pi_{De} (P'_{ab}(Nu)) (P'_{ab}(De)) \pi_{ab} = -\Pi_{Nu} \Pi_{De} \Pi_{NuDe}, \quad (\text{two of this}),$$

where $\Pi_{NuDe} =$

$$\begin{aligned} \sum_a \sum_b \frac{1}{\omega_a} \left(\sum_{s>b} [(1 - \gamma_B) \pi_{BE,s} + \gamma_B \pi_{BB,s}] [\gamma_A I(a = AA) + (1 - \gamma_A) I(a = AE)] \right. \\ \left. + \sum_{b>u} [(1 - \gamma_A) \pi_{AE,u} + \gamma_A \pi_{AA,u}] [\gamma_B I(a = BB) + (1 - \gamma_B) I(a = BE)] \right) \times \\ \left(\sum_{s<b} [(1 - \gamma_B) \pi_{BE,s} + \gamma_B \pi_{BB,s}] [\gamma_A I(a = AA) + (1 - \gamma_A) I(a = AE)] \right. \\ \left. + \sum_{b<u} [(1 - \gamma_A) \pi_{AE,u} + \gamma_A \pi_{AA,u}] [\gamma_B I(a = BB) + (1 - \gamma_B) I(a = BE)] \right) \pi_{ab}; \quad (26) \end{aligned}$$

and,

$$\sum_a \sum_b \frac{1}{\omega_a} \Pi_{Nu}^2 (P'_{ab}(De))^2 \pi_{ab} = \Pi_{Nu}^2 \Pi_{DeDe},$$

where Π_{DeDe}

$$\begin{aligned}
&= \sum_a \sum_b \frac{1}{\omega_a} \left(\sum_{s < b} [(1 - \gamma_B)\pi_{BE,s} + \gamma_B\pi_{BB,s}] [\gamma_A I(a = AA) + (1 - \gamma_A)I(a = AE)] \right. \\
&\quad \left. + \sum_{b < u} [(1 - \gamma_A)\pi_{AE,u} + \gamma_A\pi_{AA,u}] [\gamma_B I(a = BB) + (1 - \gamma_B)I(a = BE)] \right)^2 \pi_{ab}, \quad (27)
\end{aligned}$$

(28)

Adding the above four terms we have,

$$\begin{aligned}
&= \Pi_{De}^2 \Pi_{NuNu} - 2\Pi_{Nu}\Pi_{De}\Pi_{NuDe} + \Pi_{Nu}^2 \Pi_{DeDe} \\
&= \Pi_{De}^2 \left[\Pi_{NuNu} - 2\frac{\Pi_{Nu}}{\Pi_{De}}\Pi_{NuDe} + \frac{\Pi_{Nu}^2}{\Pi_{De}^2}\Pi_{DeDe} \right] \\
&= \Pi_{De}^2 [\Pi_{NuNu} - 2\eta\Pi_{NuDe} + \eta^2\Pi_{DeDe}] \\
&= \Pi_{De}^2 \sum_a \sum_b \frac{1}{\omega_a} \pi_{ab} \times \\
&\quad \left[\left(\sum_{s > b} [(1 - \gamma_B)\pi_{BE,s} + \gamma_B\pi_{BB,s}] [\gamma_A I(a = AA) + (1 - \gamma_A)I(a = AE)] \right. \right. \\
&\quad \left. \left. + \sum_{b > u} [(1 - \gamma_A)\pi_{AE,u} + \gamma_A\pi_{AA,u}] [\gamma_B I(a = BB) + (1 - \gamma_B)I(a = BE)] \right) \right. \\
&\quad \left. - \eta_{d^{(3)},d^{(1)}}^{DP} \left(\sum_{s < b} [(1 - \gamma_B)\pi_{BE,s} + \gamma_B\pi_{BB,s}] [\gamma_A I(a = AA) + (1 - \gamma_A)I(a = AE)] \right. \right. \\
&\quad \left. \left. + \sum_{b < u} [(1 - \gamma_A)\pi_{AE,u} + \gamma_A\pi_{AA,u}] [\gamma_B I(a = BB) + (1 - \gamma_B)I(a = BE)] \right) \right]^2. \quad (29)
\end{aligned}$$

In (23), the part that **do not** involve $\delta_{bb'}$ is:

$$\begin{aligned}
&\sum_a \sum_b \sum_{a'} \sum_{b'} [\Pi_{De} P'_{ab}(Nu) - \Pi_{Nu} P'_{ab}(De)] [\Pi_{De} P'_{a'b'}(N) - \Pi_{Nu} P'_{a'b'}(D)] \\
&\quad \times \frac{1}{\omega_a} \delta_{aa'} [-\pi_{ab}\pi_{a'b'}]. \quad (30)
\end{aligned}$$

The above is non-zero if $a = a'$. So we can rewrite the above as

$$\begin{aligned}
& - \sum_a \sum_b \sum_{b'} [\Pi_{De} P'_{ab}(Nu) - \Pi_{Nu} P'_{ab}(De)] [\Pi_{De} P'_{a'b'}(N) - \Pi_{Nu} P'_{a'b'}(D)] \cdot \frac{1}{\omega_a} \pi_{ab} \pi_{a'b'} \\
&= - \sum_a \frac{1}{\omega_a} \left\{ \sum_b [\Pi_{De} P'_{ab}(Nu) - \Pi_{Nu} P'_{ab}(De)] \pi_{ab} \right\} \left\{ \sum_{b'} [\Pi_{De} P'_{ab'}(N) - \Pi_{Nu} P'_{ab'}(D)] \pi_{ab'} \right\} \\
&= - \sum_a \frac{1}{\omega_a} \left\{ \sum_b [\Pi_{De} P'_{ab}(Nu) - \Pi_{Nu} P'_{ab}(De)] \pi_{ab} \right\}^2 \\
&= - \Pi_{De}^2 \sum_a \frac{1}{\omega_a} \left\{ \sum_b [P'_{ab}(Nu) - \eta_{d(3),d(1)}^{DP} P'_{ab}(De)] \pi_{ab} \right\}^2 \\
&= - \Pi_{De}^2 \left[\frac{1}{\omega_{AA}} (\gamma_A^2 \times \right. \\
&\quad \left. \left\{ \sum_b \pi_{AA,b} \left\{ \sum_{s>b} ((1 - \gamma_B) \pi_{BE,s} + \gamma_B \pi_{BB,s}) - \eta_{d(3),d(1)}^{DP} \sum_{s<b} ((1 - \gamma_B) \pi_{BE,s} + \gamma_B \pi_{BB,s}) \right\} \right\}^2 \right. \\
&+ \frac{1}{\omega_{AE}} (1 - \gamma_A)^2 \times \\
&\quad \left. \left\{ \sum_b \pi_{AE,b} \left\{ \sum_{s>b} ((1 - \gamma_B) \pi_{BE,s} + \gamma_B \pi_{BB,s}) - \eta_{d(3),d(1)}^{DP} \sum_{s<b} ((1 - \gamma_B) \pi_{BE,s} + \gamma_B \pi_{BB,s}) \right\} \right\}^2 \right. \\
&+ \frac{1}{\omega_{BB}} \gamma_B^2 \times \\
&\quad \left. \left\{ \sum_b \pi_{BB,b} \left\{ \sum_{b>u} ((1 - \gamma_A) \pi_{AE,u} + \gamma_A \pi_{AA,u}) - \eta_{d(3),d(1)}^{DP} \sum_{b<u} ((1 - \gamma_A) \pi_{AE,u} + \gamma_A \pi_{AA,u}) \right\} \right\}^2 \right. \\
&+ \frac{1}{\omega_{BE}} (1 - \gamma_B)^2 \times \\
&\quad \left. \left\{ \sum_b \pi_{BE,b} \left\{ \sum_{b>u} ((1 - \gamma_A) \pi_{AE,u} + \gamma_A \pi_{AA,u}) - \eta_{d(3),d(1)}^{DP} \sum_{b<u} ((1 - \gamma_A) \pi_{AE,u} + \gamma_A \pi_{AA,u}) \right\} \right\}^2 \right] \\
&= - \Pi_{De}^2 \sum_a \frac{1}{\omega_a} \times \\
&\quad \left[\sum_b \pi_{ab} \left\{ \left(\sum_{s>b} [(1 - \gamma_B) \pi_{BE,s} + \gamma_B \pi_{BB,s}] [\gamma_A I(a = AA) + (1 - \gamma_A) I(a = AE)] \right. \right. \right. \\
&\quad \left. \left. \left. + \sum_{b>u} [(1 - \gamma_A) \pi_{AE,u} + \gamma_A \pi_{AA,u}] [\gamma_B I(a = BB) + (1 - \gamma_B) I(a = BE)] \right) \right. \right. \\
&\quad \left. \left. - \eta_{d(3),d(1)}^{DP} \left(\sum_{s<b} [(1 - \gamma_B) \pi_{BE,s} + \gamma_B \pi_{BB,s}] [\gamma_A I(a = AA) + (1 - \gamma_A) I(a = AE)] \right. \right. \right. \\
&\quad \left. \left. \left. + \sum_{b<u} [(1 - \gamma_A) \pi_{AE,u} + \gamma_A \pi_{AA,u}] [\gamma_B I(a = BB) + (1 - \gamma_B) I(a = BE)] \right) \right) \right]^2. \quad (31)
\end{aligned}$$

Hence the asymptotic variance of $\sqrt{N} \cdot [P_{Nu}\Pi_{De} - P_{De}\Pi_{Nu}]$ is obtained by adding (29) and (31).

Finally, using (20), (21), (29) and (31), we have

$$\begin{aligned}
& \sqrt{N}(\hat{\eta}_{d^{(3)},d^{(1)}}^{\text{DP}} - \eta_{d^{(3)},d^{(1)}}^{\text{DP}}) \rightarrow \text{Normal}(0, \sigma_{d^{(3)},d^{(1)}}^2), \text{ where} \tag{32} \\
& \sigma_{d^{(3)},d^{(1)}}^2 \\
&= \frac{1}{\Pi_{De}^2} \sum_a \frac{1}{\omega_a} \left\{ \sum_b \pi_{ab} \times \right. \\
& \quad \left[\left(\sum_{s>b} [(1-\gamma_B)\pi_{BE,s} + \gamma_B\pi_{BB,s}] [\gamma_A I(a=AA) + (1-\gamma_A)I(a=AE)] \right. \right. \\
& \quad \left. \left. + \sum_{b>u} [(1-\gamma_A)\pi_{AE,u} + \gamma_A\pi_{AA,u}] [\gamma_B I(a=BB) + (1-\gamma_B)I(a=BE)] \right) \right. \\
& \quad \left. - \eta_{d^{(3)},d^{(1)}}^{\text{DP}} \left(\sum_{s<b} [(1-\gamma_B)\pi_{BE,s} + \gamma_B\pi_{BB,s}] [\gamma_A I(a=AA) + (1-\gamma_A)I(a=AE)] \right. \right. \\
& \quad \left. \left. + \sum_{b<u} [(1-\gamma_A)\pi_{AE,u} + \gamma_A\pi_{AA,u}] [\gamma_B I(a=BB) + (1-\gamma_B)I(a=BE)] \right) \right]^2 \\
& - \left[\sum_b \pi_{ab} \left\{ \left(\sum_{s>b} [(1-\gamma_B)\pi_{BE,s} + \gamma_B\pi_{BB,s}] [\gamma_A I(a=AA) + (1-\gamma_A)I(a=AE)] \right. \right. \right. \\
& \quad \left. \left. + \sum_{b>u} [(1-\gamma_A)\pi_{AE,u} + \gamma_A\pi_{AA,u}] [\gamma_B I(a=BB) + (1-\gamma_B)I(a=BE)] \right) \right. \\
& \quad \left. - \eta_{d^{(3)},d^{(1)}}^{\text{DP}} \left(\sum_{s<b} [(1-\gamma_B)\pi_{BE,s} + \gamma_B\pi_{BB,s}] [\gamma_A I(a=AA) + (1-\gamma_A)I(a=AE)] \right. \right. \\
& \quad \left. \left. + \sum_{b<u} [(1-\gamma_A)\pi_{AE,u} + \gamma_A\pi_{AA,u}] [\gamma_B I(a=BB) + (1-\gamma_B)I(a=BE)] \right) \right] \left. \right\} \tag{33}
\end{aligned}$$

12.3. Asymptotic Distribution of dGOR for shared-path

The expression of the asymptotic variance of $\sqrt{N}(\hat{\eta}_{d^{(2)},d^{(1)}}^{\text{SP}} - \eta_{d^{(2)},d^{(1)}}^{\text{SP}})$ is same as in (33) with the replacement of $d^{(3)}$ by $d^{(2)}$ and γ_B by γ_A . However, the derivation is different from Section 12.2 due to shared component of two shared-path regimes under consideration. **The derivation is shown in Supplementary Material.**

12.4. The asymptotic variance of $\log(\hat{\eta}_{g,g'}^{DP(K)})$

The asymptotic variance of $\log(\hat{\eta}_{g,g'}^{DP(K)})$ can be calculated in the same way as in Section 12.2. The asymptotic variance of $\log(\hat{\eta}_{g,g'}^{DP(K)})$ is given by $N^{-1}\sigma_{g,g'}^2(K)$, where

$$\begin{aligned} & \sigma_{g,g'}^2(K) \\ &= \frac{1}{\Pi_{De}^2} \sum_a \frac{1}{\omega_a} \left\{ \sum_b \pi_{ab} \times \left[\left(\sum_{s>b} V_s + \sum_{b>u} V_j \right) - \eta_{d^{(3)},d^{(1)}}^{DP} \left(\sum_{s<b} V_s + \sum_{b<u} V_j \right) \right]^2 \right. \\ & \quad \left. - \left[\sum_b \pi_{ab} \left(\left(\sum_{s>b} V_s + \sum_{b>u} V_j \right) - \eta_{d^{(3)},d^{(1)}}^{DP} \left(\sum_{s<b} V_s + \sum_{b<u} V_j \right) \right) \right]^2 \right\}, \end{aligned} \quad (34)$$

where Π_{De} is the denominator of $\eta_{g,g'}^{DP(K)}$,

$$\begin{aligned} V_s &= I(a = 0g'(K)) \times (1 - \gamma_{A_{K-1}})(1 - \gamma_{A_{K-2}}) \cdots (1 - \gamma_{A_1}) \\ & \quad \times \left[(1 - \gamma_{B_{K-1}})(1 - \gamma_{B_{K-2}}) \cdots (1 - \gamma_{B_1}) \pi_{B_1 B_2 \cdots B_K, s} \right. \\ & \quad \left. + \sum_{k=2}^K \gamma_{B_{k-1}} (1 - \gamma_{B_{k-2}}) \cdots (1 - \gamma_{B_1}) \pi_{B_1 B_2 \cdots B_{k-1}, s} \right] \\ & + \left[\sum_{k'=2}^K I(a = 1g'(k')) \times \gamma_{A_{k'-1}} (1 - \gamma_{A_{k'-2}}) \cdots (1 - \gamma_{A_1}) \right. \\ & \quad \times \left[(1 - \gamma_{B_{K-1}})(1 - \gamma_{B_{K-2}}) \cdots (1 - \gamma_{B_1}) \pi_{B_1 B_2 \cdots B_K, s} \right. \\ & \quad \left. + \sum_{k=2}^K \gamma_{B_{k-1}} (1 - \gamma_{B_{k-2}}) \cdots (1 - \gamma_{B_1}) \pi_{B_1 B_2 \cdots B_{k-1}, s} \right], \end{aligned}$$

and

$$\begin{aligned} V_j &= I(a = 0g(K)) \times (1 - \gamma_{B_{K-1}})(1 - \gamma_{B_{K-2}}) \cdots (1 - \gamma_{B_1}) \\ & \quad \times \left[(1 - \gamma_{A_{K-1}})(1 - \gamma_{A_{K-2}}) \cdots (1 - \gamma_{A_1}) \pi_{A_1 A_2 \cdots A_K, u} \right. \\ & \quad \left. + \sum_{k'=2}^K \gamma_{A_{k'-1}} (1 - \gamma_{A_{k'-2}}) \cdots (1 - \gamma_{A_1}) \pi_{A_1 A_2 \cdots A_{k-1}, u} \right] \\ & + \left[\sum_{k=2}^K I(a = 1g(k)) \times \gamma_{B_{k-1}} (1 - \gamma_{B_{k-2}}) \cdots (1 - \gamma_{B_1}) \right. \\ & \quad \times \left[(1 - \gamma_{A_{K-1}})(1 - \gamma_{A_{K-2}}) \cdots (1 - \gamma_{A_1}) \pi_{A_1 A_2 \cdots A_K, u} \right. \\ & \quad \left. + \sum_{k'=2}^K \gamma_{A_{k'-1}} (1 - \gamma_{A_{k'-2}}) \cdots (1 - \gamma_{A_1}) \pi_{A_1 A_2 \cdots A_{k-1}, u} \right]. \end{aligned}$$

Note that, for $K = 2, g = 3$ and $g' = 1$, $\sigma_{g,g'}^2(K)$ in (34) boils down to $\sigma_{d^{(3)},d^{(1)}}^2$ in (33).

13. SUPPLEMENTARY MATERIAL

The supplementary material includes discussion on “unrestricted” SMART with simulation, asymptotic distribution of $dGOR$ for comparison of two shared-path regimes, additional analysis of STAR*D data with four ordinal outcome categories.

REFERENCES

- AGRESTI, A. (1980). Generalized odds ratios for ordinal data. *Biometrics* **36**, 59–67.
- AGRESTI, A. (1990). *Categorical data analysis*. A Wiley-Interscience publication. New York: Wiley.
- ALMIRALL, D., NAHUM-SHANI, I., SHERWOOD, N. E. & MURPHY, S. A. (2014). Introduction to smart designs for the development of adaptive interventions: with application to weight loss research. *Translational Behavioral Medicine* **4**, 260–274.
- AUYEUNG, S., LONG, Q., ROYSTER, E., MURTHY, S., MCNUTT, M., LAWSON, D., MILLER, A., MANATUNGA, A. & MUSSELMAN, D. (2009). Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy. *Clinical Trials* **6**, 480–490.
- CHAKRABORTY, B., GHOSH, P., MOODIE, E. E. M. & RUSH, A. J. (2016). Estimating optimal shared-parameter dynamic regimens with application to a multistage depression clinical trial. *Biometrics* **72**, 865–876.
- CHAKRABORTY, B., LABER, E. & ZHAO, Y. (2013). Inference for optimal dynamic treatment regimes using an adaptive m -out-of- n bootstrap scheme. *Biometrics* **69**, 714–723.
- CHAKRABORTY, B. & MOODIE, E. (2013). *Statistical Methods for Dynamic Treatment Regimes: Reinforcement Learning, Causal Inference, and Personalized Medicine*. New York: Springer.
- CHAKRABORTY, B., MURPHY, S. & STRECHER, V. (2010). Inference for non-regular parameters in optimal dynamic treatment regimes. *Statistical Methods in Medical Research* **19**, 317–343.
- COLLINS, L. M. (2018). *Optimization of behavioral, biobehavioral, and biomedical interventions: The multiphase optimization strategy (MOST)*. New York, NY: Springer International Publishing.
- DAWSON, R. & LAVORI, P. (2004). Placebo-free designs for evaluating new mental health treatments: The use of adaptive treatment strategies. *Statistics in Medicine* **23**, 3249–3262.
- FAN, C., LU, W., SONG, R. & ZHOU, Y. (2017). Concordance-assisted learning for estimating optimal individualized treatment regimes. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* **79**, 1565–1582.
- FAVA, M., RUSH, A., TRIVEDI, M., NIERENBERG, A., THASE, M., SACKEIM, H., QUITKIN, F., WISNIEWSKI, S., LAVORI, P., ROSENBAUM, J. & KUPFER, D. (2003). Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. *Psychiatric Clinics of North America* **26**, 457–494.
- FENG, W. & WAHED, A. (2008). Supremum weighted log-rank test and sample size for comparing two-stage adaptive treatment strategies. *Biometrika* **95**, 695–707.
- FENG, W. & WAHED, A. (2009). Sample size for two-stage studies with maintenance therapy. *Statistics in Medicine* **28**, 2028–2041.
- GHOSH, P., CHEUNG, Y. & CHAKRABORTY, B. (2015). *Adaptive Treatment Strategies in Practice: Planning Trials and Analyzing Data for Personalized Medicine*, chap. Sample size calculations for clustered SMART designs. SIAM.
- GOODMAN, L. A. & KRUSKAL, W. H. (1954). Measures of association for cross classifications. *Journal of the American Statistical Association* **49**, 732–764.
- GOODMAN, L. A. & KRUSKAL, W. H. (1963). Measures of association for cross classifications III: Approximate sampling theory. *Journal of the American Statistical Association* **58**, 310–364. Doi:10.2307/2283271.
- GOODMAN, L. A. & KRUSKAL, W. H. (1972). Measures of association for cross classifications, IV: Simplification of asymptotic variances. *Journal of the American Statistical Association* **67**, 415–421. Doi:10.2307/2284396.
- JONES, H. (2010). Reinforcement-Based Treatment for Pregnant Drug Abusers (HOME II) Bethesda, MD: National Institutes of Health. <http://clinicaltrials.gov/ct2/show/NCT01177982?term=jones+pregnant&rank=9>.
- JUPP, T., LOWE, R., STEPHENSON, D. & COELHO, C. (2012). On the visualization, verification and recalibration of ternary probabilistic forecasts. *Philosophical Transactions of the Royal Society* **370**, 1100–1120.
- KASARI, C. (2009). Developmental and Augmented Intervention for Facilitating Expressive Language (CCNIA) Bethesda, MD: national Institutes of Health. <http://clinicaltrials.gov/ct2/show/NCT01013545?term=kasari&rank=5>.

- KIDWELL, K. & WAHED, A. (2013). Weighted log-rank statistic to compare shared-path adaptive treatment strategies. *Biostatistics* **14**, 299–312.
- KILBOURNE, A., ALMIRALL, D., EISENBERG, D., WAXMONSKY, J., GOODRICH, D., FORTNEY, J., KIRCHNER, J., L.I., S., MAIN, D., BAUER, M., KYLE, J., MURPHY, S., K.M., N. & M.R., T. (2014). Protocol: Adaptive Implementation of Effective Programs Trial (ADEPT): cluster randomized SMART trial comparing a standard versus enhanced implementation strategy to improve outcomes of a mood disorders program. *Implementation Science : IS* **9**, 132.
- LABER, E. & ZHAO, Y. (2015). Tree-based methods for individualized treatment regimes. *Biometrika* **102**, 501–514.
- LABER, E. B., MEYER, N. J., REICH, B. J., PACIFICI, K., COLLAZO, J. A. & DRAKE, J. M. (2018). Optimal treatment allocations in space and time for on-line control of an emerging infectious disease. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* **67**, 743–789.
- LAVORI, P. & DAWSON, R. (2000). A design for testing clinical strategies: Biased adaptive within-subject randomization. *Journal of the Royal Statistical Society, Series A* **163**, 29 – 38.
- LAVORI, P. & DAWSON, R. (2004). Dynamic treatment regimes: Practical design considerations. *Clinical Trials* **1**, 9 – 20.
- LEHMANN, E. L. (1998). *Elements of Large-Sample Theory*. Springer Texts in Statistics. New York: Springer.
- LEI, H., NAHUM-SHANI, I., LYNCH, K., OSLIN, D. & MURPHY, S. (2012). A SMART design for building individualized treatment sequences. *The Annual Review of Psychology* **8**, 21 – 48.
- LI, Z. & MURPHY, S. A. (2011). Sample size formulae for two-stage randomized trials with survival outcomes. *Biometrika* **98**, 503.
- LIANG, S., LU, W., SONG, R. & WANG, L. (2018). Sparse concordance-assisted learning for optimal treatment decision. *Journal of Machine Learning Research* **18**, 1–26.
- LIU, Y., ZENG, D. & WANG, Y. (2014). Use of personalized dynamic treatment regimes (DTRs) and sequential multiple assignment randomized trials (SMARTs) in mental health studies. *Shanghai Arch Psychiatry* **26**, 376–383.
- LIZOTTE, D., BOWLING, M. & MURPHY, S. (2012). Linear fitted-q iteration with multiple reward functions. *Journal of Machine Learning Research* **13**, 3253 – 3295.
- LUI, K.-J. & CHANG, K.-C. (2013). Notes on testing noninferiority in ordinal data under the parallel groups design. *Journal of Biopharmaceutical Statistics* **23**, 1294–1307.
- MATEOS, M.-V., ORIOL, A., MARTÍNEZ-LÓPEZ, J., GUTIÉRREZ, N., TERUEL, A.-I., DE PAZ, R., GARCÍA-LARAÑA, J., BENGOCHEA, E., MARTÍN, A., MEDIÁVILLA, J. D. et al. (2010). Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. *The Lancet Oncology* **11**, 934–941.
- MURPHY, S. (2003). Optimal dynamic treatment regimes (with discussions). *Journal of the Royal Statistical Society, Series B* **65**, 331 – 366.
- MURPHY, S. (2005). An experimental design for the development of adaptive treatment strategies. *Statistics in Medicine* **24**, 1455 – 1481.
- NAHUM-SHANI, I., QIAN, M., ALMIRAL, D., PELHAM, W., GNAGY, B., FABIANO, G., WAXMONSKY, J., YU, J. & MURPHY, S. (2012a). Experimental design and primary data analysis methods for comparing adaptive interventions. *Psychological Methods* **17**, 457 – 477.
- NAHUM-SHANI, I., QIAN, M., ALMIRAL, D., PELHAM, W., GNAGY, B., FABIANO, G., WAXMONSKY, J., YU, J. & MURPHY, S. (2012b). Q-learning: A data analysis method for constructing adaptive interventions. *Psychological Methods* **17**, 478 – 494.
- OETTING, A., LEVY, J., WEISS, R. & MURPHY, S. (2011). *Statistical Methodology for a SMART Design in the Development of Adaptive Treatment Strategies*. Arlington, VA: American Psychiatric Publishing, Inc., pp. 179 – 205.
- OSLIN, D. (2005). Managing alcoholism in people who do not respond to naltrexone (extend) Bethesda, MD: National Institutes of Health. <http://clinicaltrials.gov/ct2/show/NCT00115037?term=oslin&rank=8>.
- ROBINS, J. (1997). Causal inference from complex longitudinal data. In *Latent Variable Modeling and Applications to Causality: Lecture Notes in Statistics*, M. Berkane, ed. New York, NY: Springer-Verlag.
- ROBINS, J. (2004). Optimal structural nested models for optimal sequential decisions. In *Proceedings of the Second Seattle Symposium on Biostatistics*, D. Lin & P. Heagerty, eds. New York: Springer.
- ROBINS, J. M., ORELLANA, L. & ROTNITZKY, A. (2008). Estimation and extrapolation of optimal treatment and testing strategies. *Statistics in Medicine* **27**, 4678 – 4721.

- RUBIN, D. (1974). Estimating causal effects of treatments in randomized and nonrandomized studies. *Journal of Educational Psychology* **66**, 688 – 701.
- RUSH, A., FAVA, M., WISNIEWSKI, S., LAVORI, P., TRIVEDI, M., SACKEIM, H., THASE, M., NIERENBERG, A., QUITKIN, F., KASHNER, T., KUPFER, D., ROSENBAUM, J., ALPERT, J., STEWART, J., MCGRATH, P., BIGGS, M., SHORES-WILSON, K., LEBOWITZ, B., RITZ, L. & NIEDEREHE, G. (2004). Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. *Controlled Clinical Trials* **25**, 119 – 142.
- SCHNEIDER, L., TARIOT, P., LYKETSOS, C., DAGERMAN, K., DAVIS, K. & DAVIS, S. (2001). National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. *American Journal of Geriatric Psychiatry* **9**, 346 – 360.
- SHORTREED, S. & MOODIE, E. (2012). Estimating the optimal dynamic antipsychotic treatment regime: Evidence from the sequential-multiple assignment randomized CATIE Schizophrenia Study. *Journal of the Royal Statistical Society, Series C* **61**, 577 – 599.
- SONG, R., WANG, W., ZENG, D. & KOSOROK, M. R. (2015). Penalized q-learning for dynamic treatment regimens. *Statistica Sinica* **25**, 901–920.
- STRECHER, V., MCCLURE, J., ALEXANDER, G., CHAKRABORTY, B., NAIR, V., KONKEL, J., GREENE, S., COLLINS, L., CARLIER, C., WIESE, C., LITTLE, R., POMERLEAU, C. & POMERLEAU, O. (2008). Web-based smoking cessation components and tailoring depth: Results of a randomized trial. *American Journal of Preventive Medicine* **34**, 373 – 381.
- THALL, P., MILLIKAN, R. & SUNG, H. (2000). Evaluating multiple treatment courses in clinical trials. *Statistics in Medicine* **30**, 1011 – 1128.
- THALL, P., SUNG, H. & ESTEY, E. (2002). Selecting therapeutic strategies based on efficacy and death in multicourse clinical trials. *Journal of the American Statistical Association* **97**, 29 – 39.
- THALL, P. F., LOGOTHETIS, C., PAGLIARO, L. C., WEN, S., BROWN, M. A., WILLIAMS, D. & MILLIKAN, R. E. (2007). Adaptive therapy for androgen-independent prostate cancer: A randomized selection trial of four regimens. *Journal of the National Cancer Institute* **99**, 1613 – 1622.
- WAHED, A. & TSIATIS, A. (2004). Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomized designs in clinical trials. *Biometrics* **60**, 124 – 133.
- WAHED, A. & TSIATIS, A. (2006). Semiparametric efficient estimation of survival distributions in two-stage randomisation designs in clinical trials with censored data. *Biometrika* **93**, 163 – 177.
- WANG, L., ROTNITZKY, A., LIN, X., MILLIKAN, R. & THALL, P. (2012). Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. *Journal of the American Statistical Association* **107**, 493 – 508.
- YATES, F. (1934). Contingency tables involving small numbers and the χ^2 test. *Supplement to the Journal of the Royal Statistical Society* **1**, 217–235.
- ZHANG, B., TSIATIS, A., DAVIDIAN, M., ZHANG, M. & LABER, E. (2012). Estimating optimal treatment regimes from a classification perspective. *Stat* **1**, 103–114.
- ZHAO, Y., ZENG, D., LABER, E. & KOSOROK, M. (2015a). New statistical learning methods for estimating optimal dynamic treatment regimes. *Journal of the American Statistical Association* **110**, 583–598.
- ZHAO, Y., ZENG, D., LABER, E., SONG, R., YUAN, M. & KOSOROK, M. (2015b). New statistical learning methods for estimating optimal dynamic treatment regimes. *Biometrika* **102**, 151–168.
- ZHAO, Y., ZENG, D., RUSH, A. & KOSOROK, M. (2012). Estimating individual treatment rules using outcome weighted learning. *Journal of the American Statistical Association* **107**, 1106 – 1118.
- ZHAO, Y., ZENG, D., SOCINSKI, M. & KOSOROK, M. (2011). Reinforcement learning strategies for clinical trials in non-small cell lung cancer. *Biometrics* **67**, 1422 – 1433.